STOCK TITAN

Chiron Real Estate (NYSE: XRN) profit jumps on $217M rehab sale, new SHOP buys

(Moderate)
(Neutral)
Form Type
10-Q

Rhea-AI Filing Summary

Chiron Real Estate Inc., a healthcare-focused REIT, reported six‑month 2026 total revenue of $77.8M, up from $72.6M a year earlier. Net income for the six months rose sharply to $73.9M from $4.3M, primarily due to a $71.9M gain on the sale of seven inpatient rehabilitation facilities into a new joint venture valued at $217M, from which it received $211.4M in net proceeds and retained a 15% equity interest.

During 2026 the company expanded its seniors housing operating portfolio, acquiring two luxury Alexandria, Virginia communities, The Landing and The Riviera, for approximately $130M and $119M, respectively, now operated under SHOP/RIDEA structures. The investment portfolio as of June 30, 2026 consisted of 82% healthcare facilities, 16% SHOP assets, and 2% unconsolidated joint ventures and other investments.

Cash from operating activities for the first half of 2026 was $35.9M, with net cash used in investing activities of $81.7M and net cash provided by financing activities of $46.8M. The company issued $100.0M of Series C Convertible Preferred Stock and had $641.0M outstanding under its $900M unsecured credit facility, while total common dividends paid on common stock, OP Units and LTIP Units were $21.8M for the six‑month period.

Positive

  • Net income surged to $73.9M for the first half of 2026 from $4.3M a year earlier, driven largely by a $71.9M gain on the $217M sale of seven inpatient rehabilitation facilities into a new joint venture.
  • The company completed $249M of SHOP acquisitions in Alexandria, Virginia, adding two luxury seniors housing communities and diversifying its portfolio to 16% SHOP assets while retaining strong healthcare exposure.
  • Operating cash flow of $35.9M in the first half of 2026 comfortably covered $21.8M in common and unit-holder dividends, supporting the sustainability of current distribution levels.

Negative

  • None.
Total revenue H1 2026 $77,811 Six months ended June 30, 2026 total revenue
Net income H1 2026 $73,935 Six months ended June 30, 2026 net income
Gain on sale of properties $71,881 Gain on sale of investment properties for three and six months ended June 30, 2026
Operating cash flow H1 2026 $35,909 Net cash provided by operating activities, six months ended June 30, 2026
IRF portfolio sale price $217,000 Aggregate purchase price for seven inpatient rehabilitation facilities sold June 29, 2026
Preferred stock issuance $100,000 Aggregate gross proceeds from Series C Convertible Preferred Stock issued May 29 and June 2, 2026
Credit Facility outstanding $641,000 Gross borrowings under unsecured Credit Facility as of June 30, 2026
Common and unit-holder dividends H1 2026 $21,801 Dividends paid to common stockholders, OP Unit and LTIP Unit holders, six months ended June 30, 2026
RIDEA financial
"expanded its investment strategy to include seniors housing communities operated through structures permitted under the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as “RIDEA”)"
taxable REIT subsidiary financial
"participates in the operating results of qualified healthcare properties through taxable REIT subsidiaries (each, a “TRS”)"
A taxable REIT subsidiary is a separate company owned by a real estate investment trust (REIT) that can carry out business activities the REIT itself cannot without losing its special tax status, and that pays regular corporate income tax on its profits. Think of it as a REIT’s side business that handles taxable operations—such as providing services to properties or holding non‑qualifying assets—so the parent preserves tax benefits; investors watch it because it affects overall tax bills, earnings, and the REIT’s flexibility to grow revenue.
mezzanine loan financial
"On April 1, 2026, the Company originated a $3.0 million mezzanine loan secured by equity interests in an entity"
A mezzanine loan is a type of financing that sits between a primary bank loan and equity ownership: it has a lower priority for repayment than the main loan but ranks above shareholders. Think of it as a bridge loan that fills the gap when a company needs extra cash for a buyout, expansion, or project, often carrying higher interest and sometimes a small equity stake. For investors, mezzanine debt offers higher returns but more risk than senior loans and can affect shareholder value if converted into ownership.
interest rate swaps financial
"The Company has entered into interest rate swaps to hedge its interest rate risk on the Term Loan A Tranches and Term Loan B"
A contract between two parties to exchange streams of interest payments, typically swapping a fixed-rate payment for a floating-rate payment or vice versa. Think of it like two neighbors agreeing to trade the type of mortgage payments they make to reduce uncertainty or take advantage of expected rate moves; investors care because swaps change a company’s borrowing costs and risk exposure, which can materially affect cash flow, creditworthiness, and valuation.
LTIP Units financial
"Noncontrolling interest in the Company includes the LTIP Units that have been granted to directors, officers and affiliates"
LTIP units are awards given to executives and employees as part of a long-term incentive plan; they act like deferred bonuses that convert into company shares or cash only if the business meets set performance or time requirements. Investors care because LTIP units tie management pay to future results, can increase the number of outstanding shares (dilution) when they vest, and create ongoing compensation expense that can affect earnings and shareholder value.
Series C Convertible Preferred Stock financial
"the Company issued an aggregate of 1,000,000 shares of its Series C Convertible Preferred Stock, for aggregate gross proceeds of $100.0 million"
Series C convertible preferred stock is a class of investment shares issued in a later private financing round that combine safety and upside: they usually pay ahead of ordinary shares if a company pays dividends or is sold, but can be converted into common stock to share in future growth. For investors this acts like a VIP ticket with a safety net—offering priority protection while preserving the option to participate in a successful exit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How did Chiron Real Estate Inc. (XRN) perform financially in the first half of 2026?

Chiron Real Estate reported six‑month 2026 revenue of $77.8M and net income of $73.9M, up from $72.6M revenue and $4.3M net income in 2025, largely due to a $71.9M gain on property sales.

What major transactions did Chiron Real Estate Inc. (XRN) complete in 2026?

The company sold seven inpatient rehabilitation facilities to a joint venture for $217M, receiving $211.4M in net proceeds and recognizing a $71.9M gain. It also acquired two Alexandria seniors housing communities for about $249M combined.

How is Chiron Real Estate Inc.’s (XRN) portfolio allocated as of June 30, 2026?

As of June 30, 2026, Chiron’s gross investment portfolio was 82% healthcare facilities, primarily outpatient medical, 16% SHOP seniors housing operating assets, and 2% unconsolidated joint ventures and other investments, reflecting growing exposure to seniors housing operations.

What were Chiron Real Estate Inc. (XRN)’s cash flows for the first half of 2026?

For the six months ended June 30, 2026, Chiron generated $35.9M in operating cash flow, used $81.7M in investing activities, and had $46.8M provided by financing activities, resulting in a modest net increase in cash and restricted cash to $12.9M.

What capital-raising steps did Chiron Real Estate Inc. (XRN) take in 2026?

Chiron issued $100.0M of Series C Convertible Preferred Stock and $96.1M of additional preferred stock, while maintaining $641.0M outstanding on its unsecured credit facility and leaving $288.0M capacity under its 2024 common ATM program unused.

What dividends did Chiron Real Estate Inc. (XRN) pay in the first half of 2026?

The company paid $21.8M in aggregate dividends on common stock, OP Units and LTIP Units, plus $5.5M on preferred stock. Common dividends included several payments ranging from $0.16 to $0.75 per share over the period.
0001533615--12-312026Q2falseP6M25P3YP1YP3YP1Y0001533615xrn:AnnualPerformanceBasedLongTermIncentivePlanAwardsMemberxrn:AnnualIncentivePlan2026Member2026-01-012026-06-300001533615xrn:SurgicalHospitalInBeaumontTexasMemberus-gaap:SubsequentEventMember2026-08-032026-08-030001533615xrn:AtMarketOfferingProgram2026SeriesBPreferredSharesMember2026-02-012026-02-280001533615xrn:AtMarketOfferingProgram2024Member2024-01-012024-01-310001533615xrn:SeriesCCumulativeRedeemablePreferredStockMember2026-01-012026-06-300001533615xrn:UnconsolidatedJointVenturesAndOtherInvestmentsMember2026-01-012026-06-300001533615us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300001533615us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-06-300001533615us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001533615us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-06-300001533615xrn:InpatientRehabFacilitiesMember2026-01-012026-06-300001533615xrn:HealthcareFacilitiesMember2026-01-012026-06-300001533615xrn:SeniorHousingFacilitiesMember2026-01-012026-06-300001533615xrn:OutpatientSurgicalFacilityMember2026-04-012026-04-010001533615xrn:TermLoanOneTranchesMember2026-06-300001533615xrn:TermLoanBMember2026-06-300001533615us-gaap:RevolvingCreditFacilityMember2026-06-300001533615xrn:TermLoanOneTranchesMember2025-12-310001533615xrn:TermLoanBMember2025-12-310001533615us-gaap:RevolvingCreditFacilityMember2025-12-3100015336152025-10-082025-10-080001533615xrn:O2026Q2DividendsMemberxrn:SeriesCCumulativeRedeemablePreferredStockMember2026-06-020001533615xrn:O2026Q2DividendsMemberxrn:SeriesCCumulativeRedeemablePreferredStockMember2026-05-290001533615xrn:AnnualAndLongTermIncentivePlanUnitsMemberus-gaap:CommonStockMember2026-06-300001533615us-gaap:CommonStockMember2026-06-300001533615us-gaap:CommonStockMember2025-12-310001533615xrn:AnnualAndLongTermIncentivePlanUnitsMemberus-gaap:CommonStockMember2025-06-300001533615us-gaap:RevolvingCreditFacilityMember2025-10-082025-10-080001533615xrn:MapleGroveActiveAdultJointVentureMember2026-06-300001533615xrn:SeniorHousingFacilitiesMemberxrn:RivieraAlexandriaMember2026-06-010001533615xrn:SeniorHousingFacilitiesMemberxrn:LandingAlexandriaMember2026-06-010001533615xrn:FivePropertyPortfolioOfMedicalRealEstateMember2025-12-310001533615xrn:FivePropertyPortfolioOfMedicalRealEstateMember2025-01-012025-12-310001533615us-gaap:NotesPayableOtherPayablesMember2026-06-300001533615us-gaap:LineOfCreditMember2026-06-300001533615us-gaap:NotesPayableOtherPayablesMember2025-12-310001533615us-gaap:LineOfCreditMember2025-12-310001533615xrn:StockRepurchaseProgramAugust2025Member2026-06-300001533615xrn:AtMarketOfferingProgram2024Member2026-06-300001533615xrn:StockRepurchaseProgramAugust2025Member2025-01-012025-12-310001533615us-gaap:AdditionalPaidInCapitalMember2025-01-012025-06-300001533615us-gaap:PreferredStockMember2026-04-012026-06-300001533615us-gaap:PreferredStockMember2026-01-012026-06-300001533615us-gaap:CommonStockMember2025-01-012025-06-3000015336152025-09-012025-09-300001533615us-gaap:RetainedEarningsMember2026-06-300001533615us-gaap:ParentMember2026-06-300001533615us-gaap:NoncontrollingInterestMember2026-06-300001533615us-gaap:AdditionalPaidInCapitalMember2026-06-300001533615us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300001533615us-gaap:RetainedEarningsMember2026-03-310001533615us-gaap:ParentMember2026-03-310001533615us-gaap:NoncontrollingInterestMember2026-03-310001533615us-gaap:AdditionalPaidInCapitalMember2026-03-310001533615us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-3100015336152026-03-310001533615us-gaap:RetainedEarningsMember2025-12-310001533615us-gaap:ParentMember2025-12-310001533615us-gaap:NoncontrollingInterestMember2025-12-310001533615us-gaap:AdditionalPaidInCapitalMember2025-12-310001533615us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001533615us-gaap:RetainedEarningsMember2025-06-300001533615us-gaap:ParentMember2025-06-300001533615us-gaap:NoncontrollingInterestMember2025-06-300001533615us-gaap:AdditionalPaidInCapitalMember2025-06-300001533615us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001533615us-gaap:RetainedEarningsMember2025-03-310001533615us-gaap:ParentMember2025-03-310001533615us-gaap:NoncontrollingInterestMember2025-03-310001533615us-gaap:AdditionalPaidInCapitalMember2025-03-310001533615us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-3100015336152025-03-310001533615us-gaap:RetainedEarningsMember2024-12-310001533615us-gaap:ParentMember2024-12-310001533615us-gaap:NoncontrollingInterestMember2024-12-310001533615us-gaap:AdditionalPaidInCapitalMember2024-12-310001533615us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001533615us-gaap:PreferredStockMember2026-06-300001533615us-gaap:CommonStockMember2026-06-300001533615us-gaap:PreferredStockMember2026-03-310001533615us-gaap:CommonStockMember2026-03-310001533615us-gaap:PreferredStockMember2025-12-310001533615us-gaap:CommonStockMember2025-12-310001533615us-gaap:PreferredStockMember2025-06-300001533615us-gaap:CommonStockMember2025-06-300001533615us-gaap:PreferredStockMember2025-03-310001533615us-gaap:CommonStockMember2025-03-310001533615us-gaap:PreferredStockMember2024-12-310001533615us-gaap:CommonStockMember2024-12-310001533615xrn:LongTermIncentivePlan2026Member2026-06-300001533615xrn:LongTermIncentivePlan2025Member2026-06-300001533615xrn:LongTermIncentivePlan2024Member2026-06-300001533615xrn:EquityIncentivePlan2016Member2026-06-300001533615xrn:LongTermPerformanceBasedLongTermIncentivePlanAwardsMemberxrn:LongTermIncentivePlan2026Member2026-06-300001533615xrn:LongTermPerformanceBasedLongTermIncentivePlanAwardsMemberxrn:LongTermIncentivePlan2025Member2026-06-300001533615xrn:LongTermPerformanceBasedLongTermIncentivePlanAwardsMemberxrn:LongTermIncentivePlan2024Member2026-06-300001533615xrn:AnnualPerformanceBasedLongTermIncentivePlanAwardsMemberxrn:AnnualIncentivePlan2026Member2026-06-300001533615us-gaap:PerformanceSharesMember2026-03-310001533615xrn:LongTermIncentivePlan2026Member2026-01-012026-06-300001533615xrn:LongTermIncentivePlan2025Member2026-01-012026-06-300001533615xrn:LongTermIncentivePlan2024Member2026-01-012026-06-300001533615xrn:TimeBasedAwardsMemberxrn:LongTermIncentivePlanMember2026-06-300001533615xrn:TimeBasedAwardsMember2026-05-202026-05-200001533615xrn:TimeBasedAwardsMember2026-04-012026-04-010001533615xrn:TimeBasedAwardsMemberxrn:LongTermIncentivePlan2026Member2026-02-242026-02-240001533615xrn:TimeBasedAwardsMemberxrn:AnnualIncentivePlan2025Member2026-02-242026-02-240001533615xrn:LongTermPerformanceBasedLongTermIncentivePlanAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2026-01-012026-06-300001533615xrn:AnnualPerformanceBasedLongTermIncentivePlanAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2026-01-012026-06-300001533615xrn:LongTermPerformanceBasedLongTermIncentivePlanAwardsTotalStockholderReturnMember2026-01-012026-06-300001533615xrn:LongTermPerformanceBasedLongTermIncentivePlanAwardsRelativeStockholderReturnMember2026-01-012026-06-300001533615xrn:LongTermPerformanceBasedLongTermIncentivePlanAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2026-01-012026-06-300001533615xrn:AnnualPerformanceBasedLongTermIncentivePlanAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2026-01-012026-06-300001533615xrn:LongTermPerformanceBasedLongTermIncentivePlanAwardsMember2026-01-012026-06-300001533615xrn:AnnualPerformanceBasedLongTermIncentivePlanAwardsMember2026-01-012026-06-300001533615xrn:LongTermIncentivePlanMember2026-04-012026-06-300001533615xrn:LongTermIncentivePlanMember2025-04-012025-06-300001533615xrn:LongTermIncentivePlanMember2025-01-012025-06-300001533615xrn:TimeBasedAwardsMember2026-01-012026-06-300001533615xrn:PerformanceBasedAwardsMember2026-01-012026-06-300001533615xrn:SeriesCCumulativeRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-06-300001533615xrn:SeriesBCumulativeRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-06-300001533615xrn:SeriesACumulativeRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-06-300001533615us-gaap:CommonStockMember2026-01-012026-06-300001533615xrn:StockRepurchaseProgramAugust2025Member2026-01-012026-06-300001533615xrn:AtMarketOfferingProgram2026SeriesBPreferredSharesMember2026-01-012026-06-300001533615xrn:AtMarketOfferingProgram2024Member2026-01-012026-06-300001533615xrn:SeriesCCumulativeRedeemablePreferredStockMemberus-gaap:PrivatePlacementMember2026-05-292026-06-020001533615xrn:TenantImprovementsMember2026-06-300001533615xrn:IntangiblesMember2026-06-300001533615us-gaap:LandMember2026-06-300001533615us-gaap:LandImprovementsMember2026-06-300001533615us-gaap:FurnitureAndFixturesMember2026-06-300001533615us-gaap:BuildingMember2026-06-300001533615xrn:TenantImprovementsMember2025-12-310001533615xrn:IntangiblesMember2025-12-310001533615us-gaap:LandMember2025-12-310001533615us-gaap:LandImprovementsMember2025-12-310001533615us-gaap:FurnitureAndFixturesMember2025-12-310001533615us-gaap:BuildingMember2025-12-310001533615xrn:TenantImprovementsMember2024-12-310001533615xrn:IntangiblesMember2024-12-310001533615us-gaap:LandMember2024-12-310001533615us-gaap:LandImprovementsMember2024-12-310001533615us-gaap:BuildingMember2024-12-310001533615xrn:SurpriseMemberxrn:TenantImprovementsMember2026-01-012026-06-300001533615xrn:SurpriseMemberxrn:IntangiblesMember2026-01-012026-06-300001533615xrn:SurpriseMemberus-gaap:LandMember2026-01-012026-06-300001533615xrn:SurpriseMemberus-gaap:LandImprovementsMember2026-01-012026-06-300001533615xrn:SurpriseMemberus-gaap:BuildingMember2026-01-012026-06-300001533615xrn:ShermanIrfLtachMemberxrn:TenantImprovementsMember2026-01-012026-06-300001533615xrn:ShermanIrfLtachMemberus-gaap:LandMember2026-01-012026-06-300001533615xrn:ShermanIrfLtachMemberus-gaap:BuildingMember2026-01-012026-06-300001533615xrn:OklahomaCityFacilityMemberxrn:TenantImprovementsMember2026-01-012026-06-300001533615xrn:OklahomaCityFacilityMemberxrn:IntangiblesMember2026-01-012026-06-300001533615xrn:OklahomaCityFacilityMemberus-gaap:LandMember2026-01-012026-06-300001533615xrn:OklahomaCityFacilityMemberus-gaap:LandImprovementsMember2026-01-012026-06-300001533615xrn:OklahomaCityFacilityMemberus-gaap:BuildingMember2026-01-012026-06-300001533615xrn:MesaIrfMemberxrn:TenantImprovementsMember2026-01-012026-06-300001533615xrn:MesaIrfMemberxrn:IntangiblesMember2026-01-012026-06-300001533615xrn:MesaIrfMemberus-gaap:LandMember2026-01-012026-06-300001533615xrn:MesaIrfMemberus-gaap:LandImprovementsMember2026-01-012026-06-300001533615xrn:MesaIrfMemberus-gaap:BuildingMember2026-01-012026-06-300001533615xrn:MechanicsburgIrfMemberxrn:TenantImprovementsMember2026-01-012026-06-300001533615xrn:MechanicsburgIrfMemberxrn:IntangiblesMember2026-01-012026-06-300001533615xrn:MechanicsburgIrfMemberus-gaap:LandMember2026-01-012026-06-300001533615xrn:MechanicsburgIrfMemberus-gaap:LandImprovementsMember2026-01-012026-06-300001533615xrn:MechanicsburgIrfMemberus-gaap:BuildingMember2026-01-012026-06-300001533615xrn:LasVegasIrfMemberxrn:TenantImprovementsMember2026-01-012026-06-300001533615xrn:LasVegasIrfMemberxrn:IntangiblesMember2026-01-012026-06-300001533615xrn:LasVegasIrfMemberus-gaap:LandMember2026-01-012026-06-300001533615xrn:LasVegasIrfMemberus-gaap:LandImprovementsMember2026-01-012026-06-300001533615xrn:LasVegasIrfMemberus-gaap:BuildingMember2026-01-012026-06-300001533615xrn:AltoonaIrfMemberxrn:TenantImprovementsMember2026-01-012026-06-300001533615xrn:AltoonaIrfMemberxrn:IntangiblesMember2026-01-012026-06-300001533615xrn:AltoonaIrfMemberus-gaap:LandMember2026-01-012026-06-300001533615xrn:AltoonaIrfMemberus-gaap:LandImprovementsMember2026-01-012026-06-300001533615xrn:AltoonaIrfMemberus-gaap:BuildingMember2026-01-012026-06-300001533615xrn:SurpriseMember2026-01-012026-06-300001533615xrn:ShermanIrfLtachMember2026-01-012026-06-300001533615xrn:OklahomaCityFacilityMember2026-01-012026-06-300001533615xrn:MesaIrfMember2026-01-012026-06-300001533615xrn:MechanicsburgIrfMember2026-01-012026-06-300001533615xrn:LasVegasIrfMember2026-01-012026-06-300001533615xrn:AltoonaIrfMember2026-01-012026-06-300001533615xrn:MemphisExeterMemberus-gaap:LandMember2025-01-012025-12-310001533615xrn:MemphisExeterMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:MelbourneFacilityMemberxrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:MelbourneFacilityMemberxrn:IntangiblesMember2025-01-012025-12-310001533615xrn:MelbourneFacilityMemberus-gaap:LandMember2025-01-012025-12-310001533615xrn:MelbourneFacilityMemberus-gaap:LandImprovementsMember2025-01-012025-12-310001533615xrn:MelbourneFacilityMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:GermantownFacilityMemberus-gaap:LandMember2025-01-012025-12-310001533615xrn:GermantownFacilityMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:DerbyFacilityMemberxrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:DerbyFacilityMemberxrn:IntangiblesMember2025-01-012025-12-310001533615xrn:DerbyFacilityMemberus-gaap:LandMember2025-01-012025-12-310001533615xrn:DerbyFacilityMemberus-gaap:LandImprovementsMember2025-01-012025-12-310001533615xrn:DerbyFacilityMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:CoosBayFacilityMemberxrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:CoosBayFacilityMemberxrn:IntangiblesMember2025-01-012025-12-310001533615xrn:CoosBayFacilityMemberus-gaap:LandMember2025-01-012025-12-310001533615xrn:CoosBayFacilityMemberus-gaap:LandImprovementsMember2025-01-012025-12-310001533615xrn:CoosBayFacilityMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:ChipleyFacilityMemberxrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:ChipleyFacilityMemberxrn:IntangiblesMember2025-01-012025-12-310001533615xrn:ChipleyFacilityMemberus-gaap:LandMember2025-01-012025-12-310001533615xrn:ChipleyFacilityMemberus-gaap:LandImprovementsMember2025-01-012025-12-310001533615xrn:ChipleyFacilityMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:AuroraMemberxrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:AuroraMemberxrn:IntangiblesMember2025-01-012025-12-310001533615xrn:AuroraMemberus-gaap:LandMember2025-01-012025-12-310001533615xrn:AuroraMemberus-gaap:LandImprovementsMember2025-01-012025-12-310001533615xrn:AuroraMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:MemphisExeterMember2025-01-012025-12-310001533615xrn:GermantownFacilityMember2025-01-012025-12-310001533615xrn:DerbyFacilityMember2025-01-012025-12-310001533615xrn:CoosBayFacilityMember2025-01-012025-12-310001533615xrn:ChipleyFacilityMember2025-01-012025-12-310001533615xrn:AuroraMember2025-01-012025-12-310001533615xrn:RivieraAlexandriaMemberxrn:IntangiblesMember2026-01-012026-06-300001533615xrn:RivieraAlexandriaMemberus-gaap:LandMember2026-01-012026-06-300001533615xrn:RivieraAlexandriaMemberus-gaap:LandImprovementsMember2026-01-012026-06-300001533615xrn:RivieraAlexandriaMemberus-gaap:FurnitureAndFixturesMember2026-01-012026-06-300001533615xrn:RivieraAlexandriaMemberus-gaap:BuildingMember2026-01-012026-06-300001533615xrn:LandingAlexandriaMemberxrn:IntangiblesMember2026-01-012026-06-300001533615xrn:LandingAlexandriaMemberus-gaap:LandMember2026-01-012026-06-300001533615xrn:LandingAlexandriaMemberus-gaap:LandImprovementsMember2026-01-012026-06-300001533615xrn:LandingAlexandriaMemberus-gaap:FurnitureAndFixturesMember2026-01-012026-06-300001533615xrn:LandingAlexandriaMemberus-gaap:BuildingMember2026-01-012026-06-300001533615xrn:CapitalProjectsCompletedAndPlacedInServiceMemberxrn:TenantImprovementsMember2026-01-012026-06-300001533615xrn:CapitalProjectsCompletedAndPlacedInServiceMemberus-gaap:LandImprovementsMember2026-01-012026-06-300001533615xrn:CapitalProjectsCompletedAndPlacedInServiceMemberus-gaap:BuildingMember2026-01-012026-06-300001533615xrn:TenantImprovementsMember2026-01-012026-06-300001533615xrn:RivieraAlexandriaMember2026-01-012026-06-300001533615xrn:LandingAlexandriaMember2026-01-012026-06-300001533615xrn:IntangiblesMember2026-01-012026-06-300001533615xrn:CapitalProjectsCompletedAndPlacedInServiceMember2026-01-012026-06-300001533615us-gaap:LandMember2026-01-012026-06-300001533615us-gaap:LandImprovementsMember2026-01-012026-06-300001533615us-gaap:FurnitureAndFixturesMember2026-01-012026-06-300001533615us-gaap:BuildingMember2026-01-012026-06-300001533615xrn:SlipperyRockFacilityMemberxrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:SlipperyRockFacilityMemberxrn:IntangiblesMember2025-01-012025-12-310001533615xrn:SlipperyRockFacilityMemberus-gaap:LandImprovementsMember2025-01-012025-12-310001533615xrn:SlipperyRockFacilityMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:SilverbellFacilityMemberxrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:SilverbellFacilityMemberxrn:IntangiblesMember2025-01-012025-12-310001533615xrn:SilverbellFacilityMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:DesMoinesFacilityMemberxrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:DesMoinesFacilityMemberxrn:IntangiblesMember2025-01-012025-12-310001533615xrn:DesMoinesFacilityMemberus-gaap:LandImprovementsMember2025-01-012025-12-310001533615xrn:DesMoinesFacilityMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:CliveFacilityMemberxrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:CliveFacilityMemberxrn:IntangiblesMember2025-01-012025-12-310001533615xrn:CliveFacilityMemberus-gaap:LandImprovementsMember2025-01-012025-12-310001533615xrn:CliveFacilityMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:CarondeletFacilityMemberxrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:CarondeletFacilityMemberxrn:IntangiblesMember2025-01-012025-12-310001533615xrn:CarondeletFacilityMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:CapitalProjectsCompletedAndPlacedInServiceMemberxrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:CapitalProjectsCompletedAndPlacedInServiceMemberus-gaap:LandImprovementsMember2025-01-012025-12-310001533615xrn:CapitalProjectsCompletedAndPlacedInServiceMemberus-gaap:BuildingMember2025-01-012025-12-310001533615xrn:TenantImprovementsMember2025-01-012025-12-310001533615xrn:SlipperyRockFacilityMember2025-01-012025-12-310001533615xrn:SilverbellFacilityMember2025-01-012025-12-310001533615xrn:IntangiblesMember2025-01-012025-12-310001533615xrn:DesMoinesFacilityMember2025-01-012025-12-310001533615xrn:CliveFacilityMember2025-01-012025-12-310001533615xrn:CarondeletFacilityMember2025-01-012025-12-310001533615xrn:CapitalProjectsCompletedAndPlacedInServiceMember2025-01-012025-12-310001533615us-gaap:LandImprovementsMember2025-01-012025-12-310001533615xrn:SeriesCCumulativeRedeemablePreferredStockMember2025-12-310001533615xrn:SeriesBCumulativeRedeemablePreferredStockMember2025-12-310001533615xrn:SeriesACumulativeRedeemablePreferredStockMember2025-12-310001533615xrn:SeriesCCumulativeRedeemablePreferredStockMember2025-06-300001533615xrn:SeriesBCumulativeRedeemablePreferredStockMember2025-06-300001533615xrn:SeriesBCumulativeRedeemablePreferredStockMember2026-06-300001533615xrn:SeriesACumulativeRedeemablePreferredStockMember2026-06-300001533615xrn:O2026AdividendsMemberxrn:SeriesBCumulativeRedeemablePreferredStockMember2026-01-012026-06-300001533615xrn:O2026AdividendsMemberxrn:SeriesACumulativeRedeemablePreferredStockMember2026-01-012026-06-300001533615xrn:SeriesCCumulativeRedeemablePreferredStockMember2026-06-300001533615xrn:SeriesACumulativeRedeemablePreferredStockMember2025-01-012025-06-300001533615xrn:AnnualAndLongTermIncentivePlanUnitsMemberus-gaap:CommonStockMember2026-01-012026-06-300001533615xrn:AnnualAndLongTermIncentivePlanUnitsMemberus-gaap:CommonStockMember2025-01-012025-06-300001533615xrn:OperatingPartnershipUnitsMember2025-01-012025-12-310001533615us-gaap:RelatedPartyMember2026-06-300001533615us-gaap:RelatedPartyMember2025-12-310001533615xrn:SeniorsHousingOperatingPropertiesSegmentMember2026-04-012026-06-300001533615xrn:HealthcareRealEstateSegmentMember2026-04-012026-06-300001533615xrn:SeniorsHousingOperatingPropertiesSegmentMember2026-01-012026-06-300001533615xrn:HealthcareRealEstateSegmentMember2026-01-012026-06-300001533615xrn:HealthcareRealEstateSegmentMember2025-04-012025-06-300001533615xrn:HealthcareRealEstateSegmentMember2025-01-012025-06-300001533615xrn:OutpatientSurgicalFacilityMember2026-06-300001533615xrn:IrfJointVentureMember2026-06-300001533615xrn:HeitmanJointVentureMember2024-12-310001533615xrn:IrfJointVentureMemberxrn:IrfJointVenturePartnerMember2026-06-290001533615xrn:JointVentureDeveloperMemberxrn:HudsonActiveAdultJointVentureMember2026-05-130001533615xrn:JointVentureDeveloperMemberxrn:MapleGroveActiveAdultJointVentureMember2026-01-060001533615xrn:HeitmanJointVentureMemberxrn:HeitmanGlobalRealEstateReitLlcMember2024-12-310001533615xrn:ScenarioDebtCovenantTermsMember2025-10-080001533615xrn:MasterNoteAndGuarantyAgreementMemberus-gaap:SeniorNotesMember2026-06-300001533615us-gaap:NotesPayableToBanksMember2026-06-300001533615us-gaap:NotesPayableToBanksMember2025-12-310001533615xrn:TermLoanOneMember2025-10-080001533615xrn:TermLoanMember2025-10-080001533615xrn:TermLoanBMember2025-10-080001533615xrn:TermLoanA3Member2025-10-080001533615xrn:TermLoanA2Member2025-10-080001533615xrn:TermLoanA1Member2025-10-080001533615us-gaap:RevolvingCreditFacilityMember2025-10-0800015336152025-10-080001533615xrn:LongtermIncentivePlanLtipMember2026-01-012026-06-300001533615xrn:ChironRealEstateGpLlcMember2026-01-012026-06-300001533615srt:MinimumMember2026-06-300001533615srt:MaximumMember2026-06-300001533615xrn:OutpatientSurgicalFacilityMember2026-04-010001533615us-gaap:LandMember2025-01-012025-12-310001533615us-gaap:BuildingMember2025-01-012025-12-310001533615xrn:AuroraMember2025-08-012025-08-310001533615xrn:MelbourneFacilityMember2025-01-012025-12-310001533615xrn:InpatientRehabFacilitiesMember2026-06-292026-06-2900015336152025-01-012025-12-310001533615xrn:IrfJointVentureMember2026-06-292026-06-290001533615xrn:BelowMarketLeaseMember2026-06-300001533615xrn:LeaseCostsMember2026-06-300001533615us-gaap:LeasesAcquiredInPlaceMember2026-06-300001533615us-gaap:AboveMarketLeasesMember2026-06-300001533615xrn:LeaseCostsMember2025-12-310001533615us-gaap:LeasesAcquiredInPlaceMember2025-12-310001533615us-gaap:AboveMarketLeasesMember2025-12-310001533615xrn:IrfJointVentureMember2026-06-290001533615xrn:HeitmanJointVentureMember2024-12-310001533615xrn:HudsonActiveAdultJointVentureMember2026-05-130001533615xrn:MapleGroveActiveAdultJointVentureMember2026-01-060001533615xrn:LongTermIncentivePlanMember2026-01-012026-06-300001533615us-gaap:RetainedEarningsMember2026-04-012026-06-300001533615us-gaap:ParentMember2026-04-012026-06-300001533615us-gaap:RetainedEarningsMember2026-01-012026-06-300001533615us-gaap:ParentMember2026-01-012026-06-300001533615us-gaap:RetainedEarningsMember2025-04-012025-06-300001533615us-gaap:ParentMember2025-04-012025-06-300001533615us-gaap:RetainedEarningsMember2025-01-012025-06-300001533615us-gaap:ParentMember2025-01-012025-06-300001533615xrn:O2026Q2DividendsMemberxrn:SeriesCCumulativeRedeemablePreferredStockMember2026-04-012026-06-300001533615xrn:O2026Q2DividendsMemberxrn:SeriesBCumulativeRedeemablePreferredStockMember2026-04-012026-06-300001533615xrn:O2026Q2DividendsMemberxrn:SeriesACumulativeRedeemablePreferredStockMember2026-04-012026-06-300001533615xrn:O2026M6DividendsMemberus-gaap:CommonStockMember2026-04-012026-06-300001533615xrn:O2026M5DividendsMemberus-gaap:CommonStockMember2026-04-012026-06-300001533615xrn:O2026M4DividendsMemberus-gaap:CommonStockMember2026-04-012026-06-300001533615xrn:O2026Q1DividendsMemberxrn:SeriesBCumulativeRedeemablePreferredStockMember2026-01-012026-03-310001533615xrn:O2026Q1DividendsMemberxrn:SeriesACumulativeRedeemablePreferredStockMember2026-01-012026-03-310001533615xrn:O2026M3DividendsMemberus-gaap:CommonStockMember2026-01-012026-03-310001533615xrn:O2026M2DividendsMemberus-gaap:CommonStockMember2026-01-012026-03-310001533615xrn:O2026M1DividendsMemberus-gaap:CommonStockMember2026-01-012026-03-310001533615xrn:O2025Q4DividendsMemberxrn:SeriesBCumulativeRedeemablePreferredStockMember2025-10-012025-12-310001533615xrn:O2025Q4DividendsMemberxrn:SeriesACumulativeRedeemablePreferredStockMember2025-10-012025-12-310001533615xrn:O2025Q4DividendsMemberus-gaap:CommonStockMember2025-10-012025-12-310001533615xrn:TermLoanOneMemberus-gaap:InterestRateSwapMember2026-06-300001533615srt:MinimumMemberxrn:TermLoanOneMemberus-gaap:InterestRateSwapMember2026-06-300001533615srt:MaximumMemberxrn:TermLoanOneMemberus-gaap:InterestRateSwapMember2026-06-300001533615xrn:TermLoanBMemberus-gaap:InterestRateSwapMember2026-06-300001533615us-gaap:InterestRateSwapMember2026-06-300001533615us-gaap:InterestRateSwapMember2025-12-310001533615xrn:MasterNoteAndGuarantyAgreementMemberus-gaap:SeniorNotesMember2026-03-022026-03-020001533615srt:WeightedAverageMember2026-01-012026-06-300001533615srt:WeightedAverageMember2025-01-012025-12-310001533615xrn:ToledoLoanMember2026-06-300001533615xrn:ToledoLoanMember2025-12-310001533615xrn:MasterNoteAndGuarantyAgreementMemberus-gaap:SeniorNotesMember2026-03-020001533615xrn:ToledoLoanMemberus-gaap:NotesPayableToBanksMember2026-06-300001533615xrn:ToledoLoanMemberus-gaap:NotesPayableToBanksMember2025-12-310001533615xrn:MapleGroveActiveAdultJointVentureMember2026-01-060001533615us-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMemberxrn:SeniorsHousingOperatingPropertiesSegmentMember2026-04-012026-06-300001533615us-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMemberxrn:SeniorsHousingOperatingPropertiesSegmentMember2026-01-012026-06-300001533615xrn:O2026M6DividendsMember2026-04-012026-06-300001533615xrn:O2026M5DividendsMember2026-04-012026-06-300001533615xrn:O2026M4DividendsMember2026-04-012026-06-300001533615xrn:O2026Q1DividendsMember2026-01-012026-03-310001533615xrn:O2026M3DividendsMember2026-01-012026-03-310001533615xrn:O2026M2DividendsMember2026-01-012026-03-310001533615xrn:O2026M1DividendsMember2026-01-012026-03-310001533615xrn:O2025Q4DividendsMember2025-10-012025-12-3100015336152024-12-3100015336152025-06-300001533615xrn:ContractToPurchaseParcelOfLandMemberus-gaap:SubsequentEventMember2026-07-102026-07-100001533615xrn:InpatientRehabFacilitiesMemberxrn:IrfJointVentureMember2026-06-292026-06-290001533615xrn:IrfJointVentureMember2026-06-292026-06-290001533615xrn:SeniorHousingFacilitiesMemberxrn:RivieraAlexandriaMember2026-06-012026-06-010001533615xrn:SeniorHousingFacilitiesMemberxrn:LandingAlexandriaMember2026-06-012026-06-010001533615xrn:HeitmanJointVentureMemberxrn:MedicalOfficeBuildingInMinneapolisMinnesotaMember2026-04-012026-06-300001533615xrn:LeaseCostsMember2026-04-012026-06-300001533615us-gaap:LeasesAcquiredInPlaceMember2026-04-012026-06-300001533615xrn:LeaseCostsMember2026-01-012026-06-300001533615us-gaap:LeasesAcquiredInPlaceMember2026-01-012026-06-300001533615xrn:LeaseCostsMember2025-04-012025-06-300001533615us-gaap:LeasesAcquiredInPlaceMember2025-04-012025-06-300001533615xrn:LeaseCostsMember2025-01-012025-06-300001533615us-gaap:LeasesAcquiredInPlaceMember2025-01-012025-06-300001533615us-gaap:NotesPayableToBanksMember2026-04-012026-06-300001533615us-gaap:NotesPayableToBanksMember2026-01-012026-06-300001533615us-gaap:NotesPayableToBanksMember2025-04-012025-06-300001533615us-gaap:NotesPayableToBanksMember2025-01-012025-06-300001533615us-gaap:NoncontrollingInterestMember2026-04-012026-06-300001533615us-gaap:NoncontrollingInterestMember2026-01-012026-06-300001533615us-gaap:NoncontrollingInterestMember2025-04-012025-06-300001533615us-gaap:NoncontrollingInterestMember2025-01-012025-06-3000015336152025-04-012025-06-3000015336152025-01-012025-06-3000015336152026-06-3000015336152025-12-310001533615xrn:StockRepurchaseProgramAugust2025Member2025-08-310001533615xrn:HeitmanJointVentureMember2026-01-012026-06-300001533615xrn:MedicalFacilityMemberus-gaap:SubsequentEventMember2026-07-282026-07-280001533615xrn:MedicalFacilityMemberus-gaap:SubsequentEventMember2026-07-2800015336152026-04-012026-06-300001533615xrn:SeriesBCumulativeRedeemablePreferredStockMember2026-01-012026-06-300001533615xrn:SeriesACumulativeRedeemablePreferredStockMember2026-01-012026-06-300001533615us-gaap:CommonStockMember2026-01-012026-06-3000015336152026-08-0300015336152026-01-012026-06-30xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesxrn:itemutr:sqftxrn:buildingxrn:property

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2026

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission file number: 001-37815

Chiron Real Estate Inc.

(Exact name of registrant as specified in its charter)

Maryland

  ​ ​ ​

46-4757266

(State or other jurisdiction of incorporation or
organization)

 

(I.R.S. Employer Identification No.)

 

 

 

 7373 Wisconsin Avenue, Suite 800

Bethesda, MD

 

20814

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (202) 524-6851

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

  ​ ​ ​

Trading Symbol(s):

  ​ ​ ​

Name of each exchange on which registered:

Common Stock, par value $0.001 per share

 

XRN

 

NYSE

Series A Preferred Stock, par value $0.001 per share

 

XRN PrA

 

NYSE

Series B Preferred Stock, par value $0.001 per share

 

XRN PrB

 

NYSE

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. þ Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ   No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer 

Accelerated filer

þ

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. The number of shares of the registrant’s common stock outstanding at August 3, 2026 was 13,237,830.

-1-

Table of Contents

TABLE OF CONTENTS

PART I   FINANCIAL INFORMATION

Item 1.

Financial Statements (Unaudited)

Condensed Consolidated Balance Sheets – June 30, 2026 and December 31, 2025

3

Condensed Consolidated Statements of Operations – Three and Six Months Ended June 30, 2026 and 2025

4

Condensed Consolidated Statements of Comprehensive Income (Loss) – Three and Six Months Ended June 30, 2026 and 2025

5

Condensed Consolidated Statements of Equity – Three and Six Months Ended June 30, 2026 and 2025

6

Condensed Consolidated Statements of Cash Flows – Six Months Ended June 30, 2026 and 2025

8

Notes to the Unaudited Condensed Consolidated Financial Statements

9

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

31

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

49

Item 4.

Controls and Procedures

49

PART II OTHER INFORMATION

Item 1.

Legal Proceedings

50

Item 1A.

Risk Factors

50

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

53

Item 3.

Defaults Upon Senior Securities

53

Item 4.

Mine Safety Disclosures

54

Item 5.

Other Information

54

Item 6.

Exhibits

55

Signatures

57

-2-

Table of Contents

CHIRON REAL ESTATE INC.

Condensed Consolidated Balance Sheets

(unaudited and in thousands, except par values)

As of

  ​ ​ ​

June 30, 2026

  ​ ​ ​

December 31, 2025

  ​ ​ ​

Assets

Investment in real estate:

Land

$

184,445

$

169,917

Building

 

1,140,464

 

1,072,124

Furniture, fixtures and equipment

5,936

Site improvements

 

24,667

 

25,741

Tenant improvements

 

69,680

 

80,397

Acquired lease intangible assets

 

140,461

 

144,573

 

1,565,653

 

1,492,752

Less: accumulated depreciation and amortization

 

(315,923)

 

(338,096)

Investment in real estate, net

 

1,249,730

 

1,154,656

Cash and cash equivalents

 

10,658

 

9,084

Restricted cash

 

2,263

 

2,805

Real estate loans receivable, net

3,024

Tenant and resident receivables, net

 

6,787

 

7,225

Due from related parties

728

162

Escrow deposits

 

2,300

 

556

Deferred assets

 

22,041

 

28,907

Derivative assets

10,898

6,102

Goodwill

5,903

5,903

Investment in unconsolidated joint ventures

32,591

1,781

Other assets

 

24,855

 

25,284

Total assets

$

1,371,778

$

1,242,465

Liabilities and Equity

Liabilities:

Credit Facility, net of unamortized debt issuance costs of $8,979 and $10,476 at June 30, 2026 and December 31, 2025, respectively

$

632,021

$

652,699

Notes payable, net of unamortized debt issuance costs of $0 at June 30, 2026 and December 31, 2025

 

1,096

 

1,153

Accounts payable and accrued expenses

 

20,970

 

18,289

Dividends payable

 

8,906

 

12,484

Security deposits

 

3,287

 

3,421

Other liabilities

 

17,617

 

19,410

Acquired lease intangible liabilities, net

 

3,816

 

4,944

Total liabilities

 

687,713

 

712,400

Commitments and Contingencies

Equity:

Preferred stock, $0.001 par value, 10,000 shares authorized; 6,155 shares and 5,155 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively (liquidation preference of $228,875 and $128,875 at June 30, 2026 and December 31, 2025, respectively)

 

220,225

 

124,106

Common stock, $0.001 par value, 100,000 shares authorized; 13,235 shares issued and outstanding at June 30, 2026 and December 31, 2025

 

13

 

13

Additional paid-in capital

 

729,514

 

729,514

Accumulated deficit

 

(303,703)

 

(349,965)

Accumulated other comprehensive income

 

10,898

 

6,102

Total Chiron Real Estate Inc. stockholders' equity

 

656,947

 

509,770

Noncontrolling interest

 

27,118

 

20,295

Total equity

 

684,065

 

530,065

Total liabilities and equity

$

1,371,778

$

1,242,465

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-3-

Table of Contents

CHIRON REAL ESTATE INC.

Condensed Consolidated Statements of Operations

(unaudited and in thousands, except per share amounts)

Three Months Ended June 30, 

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Revenue

Rental revenue

$

37,060

$

37,880

$

75,081

$

72,475

Resident fees and services

1,841

1,841

Other income

 

846

 

89

 

889

 

112

Total revenue

 

39,747

 

37,969

 

77,811

 

72,587

Expenses

General and administrative

 

5,221

6,025

10,310

9,645

Operating expenses

 

10,034

8,216

19,284

15,800

Depreciation expense

 

11,443

11,307

22,530

21,614

Amortization expense

 

3,833

3,984

7,573

7,504

Interest expense

8,806

8,009

16,039

15,176

Total expenses

 

39,337

 

37,541

 

75,736

 

69,739

Income before other income (expense)

410

428

2,075

2,848

Gain on sale of investment properties

71,881

207

71,881

1,565

Equity loss from unconsolidated joint ventures

(10)

(50)

(21)

(91)

Net income

$

72,281

$

585

$

73,935

$

4,322

Less: Preferred stock dividends

 

(2,982)

(1,455)

(5,455)

(2,911)

Less: Net (income) loss attributable to noncontrolling interest

 

(6,009)

70

(5,939)

(108)

Net income (loss) attributable to common stockholders

$

63,290

$

(800)

$

62,541

$

1,303

Net income (loss) attributable to common stockholders per share – basic and diluted

$

4.78

$

(0.06)

$

4.73

$

0.10

Weighted average shares outstanding – basic and diluted

 

13,235

13,376

13,235

13,375

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-4-

Table of Contents

CHIRON REAL ESTATE INC.

Condensed Consolidated Statements of Comprehensive Income (Loss)

(unaudited and in thousands)

Three Months Ended June 30, 

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Net income

$

72,281

$

585

$

73,935

$

4,322

Other comprehensive income (loss):

Increase (decrease) in fair value of interest rate swap agreements

 

3,680

 

(3,317)

 

4,796

 

(8,217)

Total other comprehensive income (loss)

 

3,680

 

(3,317)

 

4,796

 

(8,217)

Comprehensive income (loss)

 

75,961

 

(2,732)

 

78,731

 

(3,895)

Less: Preferred stock dividends

 

(2,982)

 

(1,455)

 

(5,455)

(2,911)

Less: Comprehensive (income) loss attributable to noncontrolling interest

 

(6,327)

 

338

 

(6,353)

545

Comprehensive income (loss) attributable to common stockholders

$

66,652

$

(3,849)

$

66,923

$

(6,261)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-5-

Table of Contents

CHIRON REAL ESTATE INC.

Condensed Consolidated Statements of Equity

(unaudited and in thousands, except per share amounts)

For the Six Months Ended June 30, 2026:

Chiron

Accumulated

Real

Additional

Other

Estate Inc.

Non-

Common Stock

Preferred Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

controlling

Total

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Income

  ​ ​ ​

Equity

  ​ ​ ​

Interest

  ​ ​ ​

Equity

Balances, December 31, 2025

 

13,235

$

13

 

5,155

$

124,106

$

729,514

$

(349,965)

$

6,102

$

509,770

$

20,295

$

530,065

Net income

 

67,996

 

67,996

 

5,939

 

73,935

Issuance of shares of preferred stock, net

1,000

96,119

96,119

96,119

Change in fair value of interest rate swap agreements

 

4,796

 

4,796

 

 

4,796

Stock-based compensation expense

 

 

 

2,607

 

2,607

Dividends to common stockholders

 

(16,279)

 

(16,279)

 

 

(16,279)

Dividends to preferred stockholders

 

(5,455)

 

(5,455)

 

 

(5,455)

Dividends to noncontrolling interest

 

 

 

(1,723)

 

(1,723)

Balances, June 30, 2026

 

13,235

$

13

 

6,155

$

220,225

$

729,514

$

(303,703)

$

10,898

$

656,947

$

27,118

$

684,065

For the Three Months Ended June 30, 2026:

Chiron

Accumulated

Real

Additional

Other

Estate

Non-

Common Stock

Preferred Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

controlling

Total

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Income

  ​ ​ ​

Equity

  ​ ​ ​

Interest

  ​ ​ ​

Equity

Balances, March 31, 2026

 

13,235

$

13

 

5,155

$

124,106

$

729,514

$

(360,640)

$

7,218

$

500,211

$

20,439

$

520,650

Net income

 

 

 

 

 

 

66,272

 

 

66,272

 

6,009

 

72,281

Issuance of shares of preferred stock, net

1,000

96,119

96,119

96,119

Change in fair value of interest rate swap agreements

3,680

3,680

3,680

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

1,378

 

1,378

Dividends to common stockholders

 

 

 

 

 

 

(6,353)

 

 

(6,353)

 

 

(6,353)

Dividends to preferred stockholders

 

 

 

 

 

 

(2,982)

 

 

(2,982)

 

 

(2,982)

Dividends to noncontrolling interest

 

 

 

 

 

 

 

 

 

(708)

 

(708)

Balances, June 30, 2026

 

13,235

$

13

 

6,155

$

220,225

$

729,514

$

(303,703)

$

10,898

$

656,947

$

27,118

$

684,065

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-6-

Table of Contents

CHIRON REAL ESTATE INC.

Condensed Consolidated Statements of Equity

(unaudited and in thousands, except per share amounts)

For the Six Months Ended June 30, 2025:

Chiron

Accumulated

Real

Additional

Other

Estate Inc.

Non-

Common Stock

Preferred Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

controlling

Total

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Income

  ​ ​ ​

Equity

  ​ ​ ​

Interest

  ​ ​ ​

Equity

Balances, December 31, 2024

13,374

$

13

 

3,105

$

74,959

$

734,277

$

(293,736)

$

18,613

$

534,126

$

21,790

$

555,916

Net income (loss)

 

 

4,214

 

 

4,214

 

108

 

4,322

LTIP Units redeemed for common stock

2

67

67

(67)

Change in fair value of interest rate swap agreements

 

 

 

(8,217)

 

(8,217)

 

 

(8,217)

Stock-based compensation expense

 

 

 

 

 

1,879

 

1,879

Dividends to common stockholders

 

 

(24,077)

 

 

(24,077)

 

 

(24,077)

Dividends to preferred stockholders

 

 

(2,911)

 

 

(2,911)

 

 

(2,911)

Dividends to noncontrolling interest

 

 

 

 

 

(1,891)

 

(1,891)

Balances, June 30, 2025

 

13,376

$

13

 

3,105

$

74,959

$

734,344

$

(316,510)

$

10,396

$

503,202

$

21,819

$

525,021

For the Three Months Ended June 30, 2025:

Chiron

Accumulated

Real

Additional

Other

Estate

Non-

Common Stock

Preferred Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

controlling

Total

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Income

  ​ ​ ​

Equity

  ​ ​ ​

Interest

  ​ ​ ​

Equity

Balances, March 31, 2025

 

13,376

$

13

 

3,105

$

74,959

$

734,344

$

(305,677)

$

13,713

$

517,352

$

20,751

$

538,103

Net income (loss)

 

 

 

 

 

 

655

 

 

655

 

(70)

 

585

Change in fair value of interest rate swap agreements

(3,317)

(3,317)

(3,317)

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

1,728

 

1,728

Dividends to common stockholders

 

 

 

 

 

 

(10,032)

 

 

(10,032)

 

 

(10,032)

Dividends to preferred stockholders

 

 

 

 

 

 

(1,456)

 

 

(1,456)

 

 

(1,456)

Dividends to noncontrolling interest

 

 

 

 

 

 

 

 

 

(590)

 

(590)

Balances, June 30, 2025

 

13,376

$

13

 

3,105

$

74,959

$

734,344

$

(316,510)

$

10,396

$

503,202

$

21,819

$

525,021

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-7-

Table of Contents

CHIRON REAL ESTATE INC.

Condensed Consolidated Statements of Cash Flows

(unaudited and in thousands)

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Operating activities

Net income

$

73,935

$

4,322

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation expense

 

22,530

 

21,614

Amortization of acquired lease intangible assets

 

6,921

 

7,046

Amortization of above market leases, net

 

296

 

392

Amortization of debt issuance costs

 

1,514

 

1,118

Stock-based compensation expense

 

2,607

 

1,879

Gain on sale of investment properties

(71,881)

(1,565)

Equity loss from unconsolidated joint ventures

21

91

Other

 

132

 

112

Changes in operating assets and liabilities:

Tenant receivables

 

331

 

(402)

Deferred assets

 

(1,060)

 

(536)

Other assets and liabilities

 

(1,673)

 

(2,059)

Accounts payable and accrued expenses

 

1,823

 

2,316

Security deposits

413

83

Net cash provided by operating activities

 

35,909

 

34,411

Investing activities

Purchase of land, buildings, and other tangible and intangible assets and liabilities

(250,929)

(70,468)

Net proceeds from sale of investment properties

211,352

9,111

Investment in unconsolidated joint ventures

(30,892)

Real estate notes receivable

(2,917)

Distribution of capital from unconsolidated joint ventures

60

58

Escrow deposits for purchase of properties

 

(1,731)

 

290

Advances made to related parties

 

(565)

 

(191)

Capital expenditures on existing real estate investments

(5,175)

(4,576)

Leasing commissions

(917)

(673)

Net cash used in investing activities

 

(81,714)

 

(66,449)

Financing activities

Net proceeds received from preferred stock offering

96,119

Repayment of notes payable

 

(57)

(264)

Proceeds from Credit Facility

 

241,100

94,500

Repayment of Credit Facility

 

(263,275)

(28,500)

Payment of debt issuance costs

(17)

Dividends paid to common stockholders, and OP Unit and LTIP Unit holders

 

(21,801)

(30,503)

Dividends paid to preferred stockholders

 

(5,233)

(2,911)

Net cash provided by financing activities

 

46,836

 

32,322

Net increase in cash and cash equivalents and restricted cash

 

1,031

 

284

Cash and cash equivalents and restricted cash—beginning of period

 

11,890

 

8,942

Cash and cash equivalents and restricted cash—end of period

$

12,921

$

9,226

Supplemental cash flow information:

Cash payments for interest

$

13,519

$

14,326

Noncash financing and investing activities:

Accrued dividends payable

$

8,906

$

11,985

Interest rate swap agreements fair value change recognized in other comprehensive income (loss)

$

4,796

$

(8,217)

LTIP Units and OP Units redeemed for common stock

$

$

67

Accrued capital expenditures and leasing commissions included in accounts payable and accrued expenses

$

1,722

$

2,284

Recognition of lease liability related to right of use asset

$

163

$

6,280

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-8-

Table of Contents

CHIRON REAL ESTATE INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(dollars in thousands, except per share amounts or as otherwise indicated)

Note 1 – Organization

Chiron Real Estate Inc. (the “Company”) is a Maryland corporation and internally managed real estate investment trust (“REIT”) that owns (i) healthcare facilities leased to physician groups and regional and national healthcare systems and (ii) seniors housing communities. The Company’s seniors housing includes independent living communities (“IL”), assisted living communities (“AL”), memory care communities (“MC”) and active adult communities. As of June 30, 2026, the Company’s total gross investment portfolio consisted of 82% healthcare facilities, primarily outpatient medical facilities, 16% seniors housing operating portfolio (“SHOP”) assets, and 2% unconsolidated joint ventures and other investments.

The Company holds its facilities and conducts its operations through a Delaware limited partnership subsidiary, Chiron Real Estate LP (the “Operating Partnership”). The Company serves as the sole general partner of the Operating Partnership through a wholly owned subsidiary of the Company, Chiron Real Estate GP LLC, a Delaware limited liability company. As of June 30, 2026, the Company owned 91.3% of the outstanding common operating partnership units (“OP Units”), with the remaining 8.7% owned by holders of long-term incentive plan units (“LTIP Units”) and third-party limited partners who contributed properties or services in exchange for OP Units.  

Note 2 – Summary of Significant Accounting Policies

Basis of presentation

The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures required for annual consolidated financial statements have been condensed or excluded pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2025. In the opinion of management, all adjustments, consisting of normal and recurring adjustments, considered necessary for a fair presentation of the interim financial statements presented have been included.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company, including the Operating Partnership, its wholly owned subsidiaries, and its equity investments in unconsolidated joint ventures. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company presents the portion of any equity investment it does not own but controls (and thus consolidates) as noncontrolling interest. Noncontrolling interest in the Company includes the LTIP Units that have been granted to directors, officers and affiliates of the Company and the OP Units held by third parties. Refer to Note 5 – “Equity” and Note 7 – “Stock-Based Compensation” for additional information regarding the OP Units and LTIP Units.

The Company classifies noncontrolling interest as a component of consolidated equity on its Condensed Consolidated Balance Sheets, separate from the Company’s total equity. The Company’s net income or loss is allocated to noncontrolling interests based on the respective ownership or voting percentage in the Operating Partnership associated with such noncontrolling interests and is removed from consolidated income or loss on the Condensed Consolidated Statements of Operations in order to derive net income or loss attributable to common stockholders. The noncontrolling ownership percentage is calculated by dividing the aggregate number of LTIP Units and OP Units by the total number of units and shares outstanding.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Actual results could differ from those estimates. The Company’s most significant assumptions and estimates are related to the valuation of real estate, purchase price allocation of acquired assets, revenue recognition including the collectability of tenant receivables and asset impairment.

-9-

Table of Contents

Cash and Cash Equivalents and Restricted Cash

The Company considers all demand deposits, cashier’s checks, money market accounts, and certificates of deposit with a maturity of three months or less to be cash equivalents. Amounts included in restricted cash represent certain security deposits received from tenants at the inception of their leases and funds held by the Company related to certain tenant reimbursements. The following table provides a reconciliation of the Company’s cash and cash equivalents and restricted cash:

As of June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

Cash and cash equivalents

 

$

10,658

 

$

6,580

Restricted cash

2,263

2,646

Total cash and cash equivalents and restricted cash

 

$

12,921

 

$

9,226

Tenant and Resident Receivables, Net

Tenant receivables consist primarily of amounts due from tenants for contractual rent and tenant reimbursements for real estate taxes, insurance, and certain other operating expenses, and are accounted for in accordance with Accounting Standards Codification (“ASC”) Topic 842 “Leases” (“ASC Topic 842”). Resident receivables consist primarily of amounts due from residents of the Company's seniors housing operating communities for monthly service fees, community fees, and ancillary services, and are accounted for in accordance with ASC Topic 842. The Company evaluates the collectability of tenant receivables at each reporting date by monitoring the creditworthiness and liquidity of its tenants and assessing historical collection experience and current economic conditions. If the collection of substantially all lease payments is no longer considered probable, the Company ceases recognizing revenue on a straight-line basis and recognizes revenue only as cash is received.

Resident receivables are recorded net of an allowance for expected credit losses estimated in accordance with ASC Topic 326 “Financial Instruments — Credit Losses” (“ASC Topic 326”) using a current expected credit loss methodology that reflects historical loss experience, aging by payor category, current portfolio conditions, and reasonable and supportable forecasts of future economic conditions.

As of June 30, 2026 and December 31, 2025, the aggregate reserve recorded against tenant and resident receivables was $350 and $350, respectively.

Real Estate Loans Receivable, Net

Real estate loans receivable consists of one mezzanine loan as of June 30, 2026. The Company did not have any real estate loans as of December 31, 2025. Generally, each mezzanine loan is collateralized by an ownership interest in the respective borrower. Interest income on loans is recognized as earned based on the terms of the loans subject to evaluation of collectability risks and is included in the Company’s consolidated statements of income. On a quarterly basis, the Company evaluates the collectability of its loan portfolio, including related interest income receivable, and establishes a reserve for loan losses. The reserve for loan losses was insignificant as of June 30, 2026.

Deferred Assets

The deferred assets balance as of June 30, 2026 and December 31, 2025 was $22,041 and $28,907, respectively. The balance for both periods consisted primarily of deferred rent receivables resulting from the recognition of rental revenue on a straight-line basis over the terms of tenant leases with contractual lease payments in accordance with ASC 842 Leases (“ASC 842”).

Derivative Assets - Interest Rate Swaps

The derivative assets balance as of June 30, 2026 and December 31, 2025, was $10,898 and $6,102, respectively. In accordance with the Company’s risk management strategy, the purpose of the interest rate swaps is to manage interest rate risk for certain of the Company’s variable-rate debt. The interest rate swaps involve the Company’s receipt of variable-rate amounts from the counterparties in exchange for the Company making fixed-rate payments over the life of the agreements. The Company accounts for derivative instruments in accordance with the provisions of ASC Topic 815, “Derivatives and Hedging.” Refer to Note 4 – “Credit Facility, Notes Payable and Derivative Instruments” for additional details.

-10-

Table of Contents

Goodwill

The Company’s goodwill balance was $5,903 as of June 30, 2026 and December 31, 2025. Goodwill represents the excess of consideration paid over the fair value of underlying identifiable net assets of businesses acquired. Goodwill has an indefinite life and is not amortized. The Company tests goodwill for impairment at the reporting unit level on an annual basis, or more frequently if events or changes in circumstances indicate potential impairment. The Company has two reporting units.

Unconsolidated Joint Ventures

Heitman OM Joint Venture

In December 2024, the Company sold certain assets to a newly formed joint venture (the “Heitman OM Joint Venture”) between the Company, through its Operating Partnership, and Heitman Global Real Estate REIT LLC (“Heitman”) and their subsidiaries. The Company holds a 12.5% ownership interest in and serves as managing member of the Heitman OM Joint Venture, and Heitman holds the remaining 87.5% ownership interest. Heitman, through its voting interest, controls the Heitman OM Joint Venture. During the three months ended June 30, 2026, the Heitman OM Joint Venture acquired an additional medical office building located near Minneapolis, Minnesota, for a purchase price of $10.3 million, with the Company contributing its 12.5% proportionate share of the purchase price in accordance with the joint venture agreement. As of June 30, 2026, the Heitman OM Joint Venture has obtained two mortgage loans with an aggregate principal balance of $22.9 million.

Maple Grove Active Adult Joint Venture

On January 6, 2026, the Company entered into a joint venture with a developer to facilitate the development of an active adult residential community near Minneapolis, Minnesota (the “Maple Grove Active Adult Joint Venture”). The Company invested $7.1 million for a 49% equity interest, with the developer retaining a 51% interest and serving as the managing member. The Maple Grove Active Adult Joint Venture obtained a construction loan with a principal balance of $31.0 million, of which $10.1 million was drawn on as of June 30, 2026.

Hudson Active Adult Joint Venture

On May 13, 2026, the Company entered into a joint venture with a developer to facilitate the development of an active adult residential community near Hudson, Wisconsin (the “Hudson Active Adult Joint Venture”). The Company invested $6.7 million for a 49% equity interest, with the developer retaining a 51% interest and serving as the managing member.

IRF Joint Venture

On June 29, 2026, the Company completed the sale of seven inpatient rehabilitation facilities (“IRFs”) to a newly formed joint venture (the “IRF Joint Venture”) between the Company, through its Operating Partnership, and a U.S. public pension fund (the “IRF JV Partner”). The portfolio was valued at an aggregate purchase price of $217 million. In connection with the transaction, the Company received net proceeds of $211.4 million, before funding its $16.3 million retained equity investment in the IRF Joint Venture, and recognized a gain on the sale of investment properties of $71.9 million. The IRF JV Partner acquired an 85% equity interest and controls the IRF Joint Venture through its voting interest, while the Company acquired a 15% equity interest, serves as manager of the joint venture, and continues to oversee asset management in exchange for a management fee. The IRF Joint Venture obtained a mortgage loan with a principal balance of $108.5 million.

The Company accounts for its joint venture investments using the equity method. Under this method, the investment is initially recorded at cost and subsequently adjusted for the Company’s share of net income or loss, as well as any cash contributions or distributions. The net equity investment is included in the “Investment in unconsolidated joint ventures” line on the Condensed Consolidated Balance Sheets, and the Company’s share of net income or loss is included in “Equity income (loss) from unconsolidated joint ventures” on the Condensed Consolidated Statements of Operations. Distributions are classified as operating cash inflows to the extent of cumulative equity in earnings recognized, with any excess classified as investing cash inflows.

-11-

Table of Contents

Other Assets

Other assets consisted of the following as of June 30, 2026 and December 31, 2025. Refer to Note 8 – “Leases” for additional details on right of use assets.

As of June 30, 

As of December 31,

  ​ ​ ​

2026

  ​ ​ ​

2025

Right of use assets

 

$

13,021

 

$

13,102

Capitalized leasing commissions, net

6,588

7,784

Capitalized construction in process costs

2,885

2,551

Prepaid assets

1,870

1,539

Capitalized software costs and miscellaneous assets, net

491

308

Total Other assets

 

$

24,855

 

$

25,284

Other Liabilities

The other liabilities balance as of June 30, 2026 and December 31, 2025 was $17,617 and $19,410, respectively. The balance as of June 30, 2026 consisted of $13,393 for right of use liabilities and $4,224 of prepaid rent. The balance as of December 31, 2025 consisted of $13,438 for right of use liabilities and $5,972 of prepaid rent. Refer to Note 8 – “Leases” for additional details on right of use liabilities.

Segment Reporting

In December 2024, the Company adopted ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” for its fiscal year 2024 annual financial statements and interim financial statements thereafter. The adoption of ASU 2023-07 did not have an impact on the Company’s financial condition, results of operations, or disclosures.

During 2026, the Company expanded its investment strategy to include seniors housing communities operated through structures permitted under the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as “RIDEA”) as permitted by the Housing and Economic Recovery Act of 2008. Through these arrangements, the Company participates in the operating results of qualified healthcare properties through taxable REIT subsidiaries (each, a “TRS”) rather than solely earning contractual rental income.

Accordingly, effective in the second quarter of 2026, the Company conducts and manages its business through two reportable operating segments: (i) healthcare real estate, which consists primarily of healthcare facilities leased to physician groups and regional and national healthcare systems (“Healthcare Real Estate”), and (ii) SHOP, which includes seniors housing communities operated through RIDEA structures.

The Company's Chief Executive Officer serves as the chief operating decision maker ("CODM"). The CODM evaluates operating performance and allocates resources primarily based on net operating income or loss by reportable segment, together with consolidated financial information, including net income or loss, liquidity, leverage, and capital availability. The CODM uses this information to assess performance and make decisions regarding the allocation of capital and other resources. There are no significant segment operating expenses that require disclosure other than the expense categories on the Company’s Consolidated Statements of Operations. See Note 10 – Segment Information for additional details.

Revenue Recognition

The Company generates revenue primarily from rental income from its outpatient medical and other properties and resident fee income from its SHOP communities. Rental income from outpatient medical and other properties is recognized in accordance with ASC 842, while resident fee income from SHOP communities is recognized as housing, care and other resident services are provided.

Outpatient Medical and Other Rental Revenue

The Company’s outpatient medical and other rental revenue operations primarily consist of rental revenue earned from tenants under leasing arrangements that provide for minimum rent and, in certain cases, rent escalations. These leases have been accounted for as operating leases. For operating leases with contingent rental escalators, revenue is recorded based on the contractual cash rental payments due during the period. Revenue from leases with fixed annual rental escalators is recognized on a straight-line basis over the

-12-

Table of Contents

initial lease term when substantially all lease income, including the related straight-line rent receivable, is probable of collection. Recognizing rental income on a straight-line basis generally results in recognized revenues during the first half of a lease term exceeding the cash amounts contractually due from tenants, creating a straight-line rent receivable that is included in deferred assets on the Company’s Condensed Consolidated Balance Sheets. At June 30, 2026 and 2025, this cumulative excess totaled $19.9 million and $27.6 million, respectively.

The Company exercises considerable judgment in the rental property revenue recognition process, including the treatment of the contractual rental stream and the determination of collectability. The Company monitors the liquidity and creditworthiness of its tenants and operators and considers available operational performance measures, including sales and the aging of billed amounts, as well as other publicly available information regarding tenant financial condition, liquidity and capital resources, including declines in such conditions. If the Company determines that lease-related receivables are not probable of collection, rental revenue is recorded on a cash basis, which generally limits rental revenue to amounts received from the tenant. The corresponding tenant receivable and straight-line rent receivable are charged as a direct write-off against rental revenue in the period of the change in the collectability determination.

The Company is also entitled to receive reimbursements from tenants for various property operating costs paid by the Company on their behalf. The Company has elected the practical expedient for lessors to account for the lease and non-lease components as a single component pursuant to ASC 842 when the lease component is predominant, the timing and pattern of transfer are the same and the lease component, if accounted for separately, would be classified as an operating lease. Accordingly, reimbursements from tenants are recognized as variable lease payments when earned and the corresponding property-level operating costs are expensed as incurred.

SHOP

SHOP resident agreements are accounted for as operating leases under ASC 842 and generally include both housing and service components. The Company has elected the practical expedient to account for the lease and non-lease components as a single lease component when the criteria under ASC 842 are met. Accordingly, revenue from resident fees, including room, care, ancillary and other service charges, is recognized monthly as housing, care and other services are provided, generally beginning when the resident occupies a home or begins receiving services. Resident agreements are generally short-term in nature and may allow for termination with 30 days’ notice. Move-in fees and certain rent incentives are recognized on a straight-line basis over the average resident stay.

For communities operated through a RIDEA structure, the applicable TRS contracts with the third-party manager and recognizes resident fee income and related operating expenses. The REIT generally leases the underlying real estate to the TRS pursuant to an intercompany lease arrangement; however, the related intercompany lease revenue and expense are eliminated in consolidation. Accordingly, consolidated revenues within the SHOP reportable segment reflect resident fee income and related service revenues generated by the communities, rather than rent from third-party operators.

Rental revenue from tenants and resident fee income from residents are recognized only to the extent collection is probable. This assessment is based on several qualitative and quantitative factors, including, as applicable, payment history, ability to satisfy contractual obligations, the value of any underlying collateral or deposit and current economic conditions. If collection is subsequently assessed as not probable, revenue recognized is limited to amounts collected, and any revenue previously recognized in excess of amounts received is reversed. If collection is later reassessed as probable, revenue is adjusted to reflect the amount that would have been recognized had collection always been assessed as probable.

New Accounting Pronouncements

In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), to address requests from investors for more detailed information about the types of expenses in commonly presented expense captions. ASU 2024-03 requires public companies to provide disaggregated disclosure in tabular format in the notes to financial statements of specific expenses, including but not limited to: (i) employee compensation, (ii) depreciation, and (iii) intangible asset amortization. In January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarifies that the amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is evaluating the impact ASU 2024-03 will have on its disclosures.

In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (“ASU 2025-11”), to improve the guidance in ASC Topic 270, Interim Reporting, including by clarifying when Topic 270 is applicable, improving the navigability of interim disclosure requirements, and establishing a principle that requires entities to disclose events since

-13-

Table of Contents

the end of the last annual reporting period that have a material impact on the entity. For public business entities, ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027 (and for entities other than public business entities, beginning after December 15, 2028). Early adoption is permitted, and the amendments may be applied retrospectively or prospectively. The Company is evaluating the impact ASU 2025-11 will have on its disclosures.

Note 3 – Property Portfolio

Summary of Properties Acquired and Sold During the Six Months Ended June 30, 2026

During the six months ended June 30, 2026, the Company completed two acquisitions of seniors housing communities and one portfolio disposition comprised of seven IRFs which were sold into the IRF Joint Venture.

On June 1, 2026, the Company completed the acquisition of The Landing Alexandria (the “Landing”), a 163-home, luxury seniors housing community located in Alexandria, Virginia, from affiliates of Silverstone Senior Living (“SSL”) for a purchase price of approximately $130 million. The Landing offers independent living, assisted living and memory care. For this acquisition, substantially all of the fair value was concentrated in a single identifiable asset or group of similar identifiable assets and, therefore, this acquisition represented an asset acquisition. Accordingly, $1.0 million of transaction costs for this acquisition were capitalized.

On June 1, 2026, the Company completed the acquisition of The Riviera at Alexandria (the “Riviera”), a 129-home, luxury seniors housing community located in Alexandria, Virginia, from affiliates of SSL for a purchase price of approximately $119 million. The Riviera offers independent living. For this acquisition, substantially all of the fair value was concentrated in a single identifiable asset or group of similar identifiable assets and, therefore, this acquisition represented an asset acquisition. Accordingly, $0.9 million of transaction costs for this acquisition were capitalized.

The Company operates the Landing and the Riviera as SHOP communities and one of its TRSs has engaged an affiliate of Greystone Communities to manage the day-to-day operations of the communities. Under this structure, the Company owns the real estate and participates directly in the operating results of the communities, including revenues and operating expenses, rather than receiving fixed lease payments from a third-party tenant.

On June 29, 2026, the Company sold seven IRFs to the IRF Joint Venture in connection with the formation of the joint venture for an aggregate purchase price of $217 million, received net proceeds of $211.4 million before funding its $16.3 million retained equity investment in the joint venture, and recognized a gain on the sale of investment properties of $71.9 million.

A rollforward of the gross investment in land, building, improvements, and acquired lease intangible assets as of June 30, 2026 is as follows:

Furniture,

Fixtures,

Site

Tenant

Acquired Lease

Gross Investment in

  ​ ​

Land

  ​ ​

Building

  ​ ​

and Equipment

  ​ ​

Improvements

  ​ ​

Improvements

  ​ ​

Intangible Assets

  ​ ​

Real Estate

Balances as of December 31, 2025

$

169,917

$

1,072,124

$

$

25,741

$

80,397

$

144,573

$

1,492,752

Facility Acquired – Date Acquired:

Landing Alexandria – 6/1/26

15,946

100,786

2,770

310

11,231

131,043

Riviera Alexandria – 6/1/26

11,171

104,924

3,166

338

287

119,886

Capitalized costs (1)

 

3,412

256

1,877

 

5,545

Total Additions:

27,117

209,122

5,936

904

1,877

11,518

256,474

Facility Sold – Date Sold:

Mesa – 6/29/26 (2)

(3,018)

(15,790)

(602)

(475)

(2,465)

(22,350)

Surprise – 6/29/26 (2)

(1,738)

(18,737)

(263)

(4,119)

(3,861)

(28,718)

Las Vegas – 6/29/26 (2)

(2,479)

(15,277)

(244)

(2,205)

(2,297)

(22,502)

Oklahoma City – 6/29/26 (2)

(2,486)

(26,315)

(143)

(3,044)

(3,155)

(35,143)

Altoona – 6/29/26 (2)

(783)

(18,362)

(400)

(143)

(1,856)

(21,544)

Mechanicsburg – 6/29/26 (2)

(484)

(21,290)

(326)

(161)

(1,996)

(24,257)

Sherman – 6/29/26 (2)

(1,601)

(25,011)

(2,447)

(29,059)

Total Dispositions:

(12,589)

(140,782)

(1,978)

(12,594)

(15,630)

(183,573)

Impairment of investment properties

Balances as of June 30, 2026

$

184,445

$

1,140,464

$

5,936

$

24,667

$

69,680

$

140,461

$

1,565,653

(1)Represents capital projects that were completed and placed in service during the six months ended June 30, 2026 related to the Company’s existing facilities.
(2)These facilities were sold to the IRF Joint Venture in connection with its formation.

-14-

Table of Contents

Depreciation expense was $11,443 and $22,530 for the three and six months ended June 30, 2026, respectively, and $11,307 and $21,614 for the three and six months ended June 30, 2025, respectively.

As of June 30, 2026, the Company had aggregate capital improvement commitments and obligations to improve, expand, and maintain the Company’s existing facilities of approximately $24,500. Many of these amounts are subject to contingencies that make it difficult to predict when they will be utilized, if at all. In accordance with the terms of the Company’s leases, capital improvement obligations in the next twelve months are expected to total approximately $15,300.

On April 1, 2026, the Company originated a $3.0 million mezzanine loan secured by equity interests in an entity that owns an under-development medical facility located in Fort Myers, Florida, of which $2.9 million was drawn as of June 30, 2026. The medical facility is an on-campus outpatient surgical facility that is 100% pre-leased to an investment-grade tenant under a 15-year lease with no termination rights. The loan bears interest at a rate of 12.0% per annum, has an initial term of 24 months, and represents approximately 10% of the total project cost. In connection with the loan, the Company holds a right of first offer and right of first refusal with respect to a sale of the property, which are subject to the pre-leased tenant’s corresponding rights.

Summary of Properties Acquired and Sold During the Year Ended December 31, 2025

During the year ended December 31, 2025, the Company completed the acquisition of a five-property portfolio of medical real estate. For this acquisition, substantially all of the fair value was concentrated in a single identifiable asset or group of similar identifiable assets and, therefore, this acquisition represented an asset acquisition. Accordingly, $1.0 million of transaction costs for this acquisition were capitalized.

During the year ended December 31, 2025, the Company completed seven dispositions for approximately $23.0 million, realizing an aggregate net gain of approximately $1.5 million. In addition, we recognized impairment losses on the sold assets of $13.0 million.

A rollforward of the gross investment in land, building, improvements, and acquired lease intangible assets as of December 31, 2025 is as follows:

Furniture,

Fixtures,

Site

Tenant

Acquired Lease

Gross Investment in

  ​ ​ ​

Land

  ​ ​ ​

Building

  ​ ​ ​

and Equipment

  ​ ​ ​

Improvements

  ​ ​ ​

Improvements

  ​ ​ ​

Intangible Assets

  ​ ​ ​

Real Estate

Balances as of December 31, 2024

$

174,300

$

1,044,019

$

$

23,973

$

69,679

$

138,945

$

1,450,916

Facility Acquired – Date Acquired:

Carondelet - 2/7/25

13,327

1,274

1,725

16,326

Silverbell - 2/7/25

8,482

973

1,368

10,823

Slippery Rock - 2/7/25

3,511

455

593

572

5,131

Clive - 4/1/25

11,400

507

1,595

2,218

15,720

Des Moines - 4/1/25

18,917

182

3,289

3,519

25,907

Capitalized costs(1)

 

5,927

1,226

5,008

 

12,161

Total Additions:

61,564

2,370

12,732

9,402

86,068

Facility Sold – Date Sold:

Derby - 2/18/25

(146)

(1,250)

(118)

(73)

(372)

(1,959)

Coos Bay - 3/19/25

(861)

(5,096)

(56)

(49)

(410)

(6,472)

Chipley - 4/30/25

(170)

(875)

(34)

(111)

(189)

(1,379)

2999 Germantown - 8/7/25

(253)

(1,593)

(1,846)

Aurora - 9/4/25

(339)

(2,345)

(308)

(603)

(2,680)

(6,275)

Memphis Exeter - 11/4/25

(232)

(1,912)

(2,144)

Melbourne - 12/30/25

(1,200)

(8,556)

(86)

(1,178)

(123)

(11,143)

Total Dispositions:

(3,201)

(21,627)

(602)

(2,014)

(3,774)

(31,218)

Impairment of investment properties(2)

(1,182)

(11,832)

(13,014)

Balances as of December 31, 2025

$

169,917

$

1,072,124

$

$

25,741

$

80,397

$

144,573

$

1,492,752

(1)

Represents capital projects that were completed and placed in service during the year ended December 31, 2025 related to the Company’s existing facilities.

(2)

In August 2025, the Company entered into an agreement to sell its facility located in Aurora, Illinois, and recognized an impairment loss of $6.3 million to reduce the carrying value of the asset to its estimated fair value. The fair value was determined based on the contractual sales price, less commissions and fees, and the sale was completed in September 2025. In December 2025, the Company entered into an agreement to sell its facility located in Melbourne, Florida, and recognized an impairment loss of $6.7 million to reduce the carrying value of the asset to its estimated fair value. The fair value was determined based on the contractual sales price, less commissions and fees, and the sale was completed in December 2025.

-15-

Table of Contents

Lease Intangible Assets and Liabilities

The following is a summary of the carrying amount of lease intangible assets and liabilities as of the dates presented:

As of June 30, 2026

Accumulated

  ​ ​ ​

Cost

  ​ ​ ​

Amortization

  ​ ​ ​

Net

Assets

In-place leases

$

83,441

$

(53,380)

$

30,061

Above market leases

 

22,644

 

(15,721)

 

6,923

Leasing costs

 

34,376

 

(24,153)

 

10,223

$

140,461

$

(93,254)

$

47,207

Liability

Below market leases

$

16,413

$

(12,597)

$

3,816

As of December 31, 2025

  ​ ​ ​

  ​ ​ ​

Accumulated

  ​ ​ ​

Cost

Amortization

Net

Assets

 

  ​

 

  ​

 

  ​

In-place leases

$

82,590

$

(58,294)

$

24,296

Above market leases

 

24,024

 

(15,258)

 

8,766

Leasing costs

 

37,959

 

(25,017)

 

12,942

$

144,573

$

(98,569)

$

46,004

Liability

 

 

 

Below market leases

$

17,335

$

(12,391)

$

4,944

The following is a summary of the acquired lease intangible amortization:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Amortization expense related to in-place leases

$

2,432

$

2,594

$

4,754

$

4,809

Amortization expense related to leasing costs

$

1,077

$

1,165

$

2,167

$

2,237

Decrease in rental revenue related to above market leases

$

709

$

735

$

1,424

$

1,490

Increase in rental revenue related to below market leases

$

(559)

$

(795)

$

(1,128)

$

(1,098)

As of June 30, 2026, scheduled future aggregate net amortization of the acquired lease intangible assets and liabilities for each year ended December 31 is listed below:

  ​ ​ ​

  ​ ​ ​

Net Decrease

Net Increase

in Revenue

in Expense

2026 (six months remaining)

$

(119)

$

6,388

2027

 

(357)

 

10,574

2028

 

(699)

 

8,119

2029

 

(751)

 

5,618

2030

(569)

3,203

Thereafter

 

(612)

 

6,382

Total

$

(3,107)

$

40,284

As of June 30, 2026, the weighted average amortization periods for asset lease intangibles and liability lease intangibles were 2.8 years and 1.8 years, respectively.

-16-

Table of Contents

Note 4 – Credit Facility, Notes Payable and Derivative Instruments

Credit Facility

On October 8, 2025, the Operating Partnership, as borrower, and certain of its subsidiaries entered into an amended and restated $900 million unsecured syndicated credit facility with JPMorgan Chase Bank, N.A. as administrative agent (the “Credit Facility”). The Credit Facility consists of (i) $500 million of term loans, which include (a) a $350 million loan that is comprised of three term loans as follows: a $100 million term loan maturing in October 2029 (“Term Loan A-1”); a $100 million term loan maturing in October 2030 (“Term Loan A-2”); and a $150 million term loan maturing in April 2031 (“Term Loan A-3,” and together with Term Loan A-1 and Term Loan A-2, the “Term Loan A Tranches”); and (b) a $150 million term loan maturing in February 2028 (“Term Loan B”), and (ii) a $400 million revolver maturing in October 2029 with two, six-month extension options available at the Company’s election (the “Revolver”). The Credit Facility also includes a $500 million accordion feature. Interest rates on amounts outstanding under the Credit Facility equal the term SOFR plus a borrowing spread based on the current pricing grid in the Credit Facility.

The Operating Partnership is subject to a number of financial covenants under the Credit Facility, including, among other things, the following as of the end of each fiscal quarter, (i) a maximum consolidated unsecured leverage ratio of less than 60%, (ii) a maximum consolidated secured leverage ratio of less than 30%, (iii) a maximum consolidated secured recourse leverage ratio of less than 10%, (iv) a minimum fixed charge coverage ratio of 1.50:1.00, (v) a minimum unsecured interest coverage ratio of 1.50:1.00, (vi) a maximum consolidated leverage ratio of less than 60%, and (vii) a minimum net worth of $595.6 million plus 75% of all net proceeds raised through equity offerings subsequent to June 30, 2025. As of June 30, 2026, management believed it complied with all of the financial and non-financial covenants contained in the Credit Facility.

The Company has entered into interest rate swaps to hedge its interest rate risk on the Term Loan A Tranches and Term Loan B through their respective maturities. For additional information related to the interest rate swaps, see the “Derivative Instruments - Interest Rate Swaps” section herein.

During the six months ended June 30, 2026, the Company borrowed $241,100 under the Credit Facility and repaid $263,275, for a net amount repaid of $22,175. During the six months ended June 30, 2025, the Company borrowed $94,500 under the Credit Facility and repaid $28,500, for a net amount borrowed of $66,000. Interest expense incurred on the Credit Facility was $8,013, and $14,355 for the three and six months ended June 30, 2026, respectively, and $7,236, and $13,698 for the three and six months ended June 30, 2025, respectively.

As of June 30, 2026 and December 31, 2025, the Company had the following outstanding borrowings under the Credit Facility:

  ​ ​ ​

June 30, 2026

  ​ ​ ​

December 31, 2025

Revolver

$

141,000

$

163,175

Term Loan A Tranches

350,000

350,000

Term Loan B

 

150,000

 

150,000

Credit Facility, gross

641,000

663,175

Less: Unamortized debt issuance costs

 

(8,979)

 

(10,476)

Credit Facility, net

$

632,021

$

652,699

Costs incurred related to the Credit Facility, net of accumulated amortization, are netted against the Company’s “Credit Facility, net of unamortized debt issuance costs” balance in the accompanying Condensed Consolidated Balance Sheets. Amortization expense incurred related to debt issuance costs was $707 and $1,514 for the three and six months ended June 30, 2026, respectively, and $550 and $1,100 for the three and six months ended June 30, 2025, respectively, and is included in the “Interest Expense” line item in the accompanying Condensed Consolidated Statements of Operations.

-17-

Table of Contents

Notes Payable, Net of Debt Issuance Costs

The Company, through certain of its wholly owned subsidiaries, may enter into or assume loans in connection with acquisitions. As of June 30, 2026 and December 31, 2025, the Company had the following outstanding borrowing in connection with the Toledo facility:

  ​ ​ ​

June 30, 2026

  ​ ​ ​

December 31, 2025

Toledo loan (1)

$

1,096

$

1,153

Unamortized debt issuance costs

 

 

Notes payable, net

$

1,096

$

1,153

(1)The Toledo loan has an annual interest rate of 5.0% and matures on July 30, 2033.

Amortization expense incurred related to debt issuance costs for notes payable was $0 for the three and six months ended June 30, 2026, and $9 and $18 for the three and six months ended June 30, 2025, respectively, and is included in the “Interest Expense” line item in the accompanying Condensed Consolidated Statements of Operations.

The Company made principal payments of $57 and $264 during the six months ended June 30, 2026 and 2025, respectively. Interest expense incurred on notes payable was $18 and $36 for the three and six months ended June 30, 2026, respectively, and $145 and $291 for the three and six months ended June 30, 2025, respectively.

As of June 30, 2026, scheduled principal payments due for each year ended December 31 were as follows:

2026 (six months remaining)

$

59

2027

124

2028

131

2029

139

2030

146

Thereafter

497

Total

$

1,096

Senior Note Facility

On March 2, 2026, the Company entered into a Master Note and Guaranty Agreement (the “Senior Note Agreement”) with NYL Investors LLC and certain of its affiliates (collectively, the “Purchasers”). The Senior Note Agreement establishes an uncommitted senior unsecured note facility pursuant to which the Company may issue senior unsecured promissory notes (“Notes”) from time to time in one or more series to the Purchasers in an aggregate principal amount of up to $150 million. The Senior Note Agreement does not obligate the Purchasers to purchase any Notes, and each issuance is subject to the Purchasers’ discretion and satisfaction of customary conditions. Notes may be issued under the Senior Note Agreement during a period ending on the earliest of (i) the third anniversary of the effective date of the Senior Note Agreement, (ii) termination of the facility by either party upon written notice, (iii) termination following certain events of default, or (iv) acceleration of the Notes and termination of the facility. Notes issued under the Senior Note Agreement may have maturities of up to ten years and will bear interest at rates determined at the time of issuance based on spreads over U.S. Treasury securities. As of June 30, 2026, no Notes had been issued or were outstanding under the Senior Note Agreement.

Derivative Instruments - Interest Rate Swaps

As of June 30, 2026, the Company had 11 interest rate swaps outstanding that are used to manage its interest rate risk by fixing the SOFR component of its term loans through their maturities, consisting of four interest rate swaps related to Term Loan B and seven interest rate swaps related to the Term Loan A Tranches. The four interest rate swaps related to Term Loan B have a combined notional value of $150 million and fix the SOFR component on Term Loan B through January 2028 at 2.54%. The seven interest rate swaps related to the Term Loan A Tranches have a combined notional value of $350 million and fix the SOFR components on the Term Loan A Tranches at rates between 3.24% to 3.32% and have maturities in October 2029, October 2030, and April 2031.

The Company records the swaps either as an asset or a liability measured at its fair value at each reporting period. When hedge accounting is applied, the change in the fair value of derivatives designated and that qualify as cash flow hedges is (i) recorded in accumulated other comprehensive income in the equity section of the Company’s Condensed Consolidated Balance Sheets and

-18-

Table of Contents

(ii) subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transactions affect earnings. If specific hedge accounting criteria are not met, changes in the Company’s derivative instruments’ fair value are recognized currently as an adjustment to net income. As of June 30, 2026 and December 31, 2025, all of the Company’s swaps met the criteria for hedge accounting.

The Company’s interest rate swaps are not traded on an exchange. The Company’s interest rate swaps are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis based on the expected size of future cash flows on a discounted basis and incorporates a measure of non-performance risk. The fair values are based on Level 2 inputs within the framework of ASC Topic 820. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivative instruments.

The fair value of the Company’s interest rate swaps was an asset of $10,898 and $6,102 as of June 30, 2026 and December 31, 2025, respectively. The balances are included in the “Derivative Assets” line item on the Company’s Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025, respectively.

The table below details the components of the amounts presented on the accompanying Condensed Consolidated Statements of Comprehensive Income (Loss) recognized on the Company’s interest rate swaps designated as cash flow hedges for the three and six months ended June 30, 2026 and 2025:

Three Months Ended June 30, 

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Amount of (gain) loss recognized in other comprehensive income (loss)

$

(4,943)

$

18

$

(8,519)

$

1,653

Amount of gain reclassified from accumulated other comprehensive income into interest expense

 

1,263

 

3,299

 

3,723

 

6,564

Total change in accumulated other comprehensive (loss) income

$

(3,680)

$

3,317

$

(4,796)

$

8,217

During the next twelve months, the Company estimates that an additional $4,286 will be reclassified as a decrease to interest expense. Additionally, during the three and six months ended June 30, 2026, the Company recorded total interest expense in its Condensed Consolidated Statements of Operations of $8,806 and $16,039, respectively.

Weighted-Average Interest Rate and Term

The weighted average interest rate and term of the Company’s debt was 4.56% and 3.6 years, respectively, at June 30, 2026, compared to 3.74% and 4.1 years as of December 31, 2025.

Note 5 – Equity

In September 2025, the Company completed a one-for-five reverse stock split of its outstanding shares of common stock, with a corresponding adjustment to the outstanding partnership units of the Operating Partnership (the “Reverse Stock Split”). Unless otherwise noted, all common share and unit amounts shown herein are shown on a split-adjusted basis.

Preferred Stock

The Company’s charter authorizes the issuance of 10,000,000 shares of preferred stock, par value $0.001 per share. As of June 30, 2026 and December 31, 2025, there were 3,105,000 shares of Series A Cumulative Redeemable Preferred Stock (“Series A Preferred Stock”) issued and outstanding, 2,050,000 shares of Series B Cumulative Redeemable Preferred Stock (“Series B Preferred Stock”) issued and outstanding, and 1,000,000 shares and 0 shares, respectively, of Series C Convertible Cumulative Redeemable Preferred Stock (“Series C Convertible Preferred Stock”) issued and outstanding. Each of the Series A Preferred Stock and Series B Preferred Stock has a liquidation preference of $25 per share, and the Series C Convertible Preferred Stock has a liquidation preference of $100 per share.

-19-

Table of Contents

Series A Preferred Stock

Series A Preferred Stock dividend activity for the six months ended June 30, 2026 is summarized in the following table:

  ​ ​ ​

  ​ ​ ​

  ​ ​ ​

Quarterly

  ​ ​ ​

Dividends

Date Announced

Record Date

Payment Date

Dividend

per Share

December 4, 2025

January 15, 2026

February 2, 2026

$

1,455

$

0.46875

February 25, 2026

April 15, 2026

April 30, 2026

$

1,455

$

0.46875

May 20, 2026

July 15, 2026

July 31, 2026

$

1,455

(1)

$

0.46875

(1)

Two months of this amount, equal to $970, was accrued at June 30, 2026.

The holders of the Series A Preferred Stock are entitled to receive dividend payments only when, as and if declared by the Board of Directors (the “Board”) (or a duly authorized committee of the Board). The Series A Preferred Stock dividends will accrue or be payable in cash from the original issue date, on a cumulative basis, quarterly in arrears on each dividend payment date at a fixed rate per annum equal to 7.50% of the liquidation preference of $25.00 per share (equivalent to $1.875 per share on an annual basis). Dividends on the Series A Preferred Stock are cumulative and accrue whether or not (i) funds are legally available for the payment of those dividends, (ii) the Company has earnings or (iii) those dividends are declared by the Board. The Series A Preferred Stock may be partially or fully redeemed by the Company. The quarterly dividend payment dates on the Series A Preferred Stock are January 31, April 30, July 31 and October 31 of each year. During each of the six-month periods ended June 30, 2026 and 2025, the Company paid preferred dividends on its Series A Preferred Stock of $2,911.

Series B Preferred Stock

Series B Preferred Stock dividend activity for the six months ended June 30, 2026 is summarized in the following table:

  ​ ​ ​

  ​ ​ ​

  ​ ​ ​

Quarterly

  ​ ​ ​

Dividends

Date Announced

Record Date

Payment Date

Dividend

per Share

December 4, 2025

January 15, 2026

February 2, 2026

$

795

$

0.388

February 25, 2026

April 15, 2026

April 30, 2026

$

1,025

$

0.500

May 20, 2026

July 15, 2026

July 31, 2026

$

1,025

(1)

$

0.500

(1)

Two months of this amount, equal to $680, was accrued at June 30, 2026.

The holders of the Series B Preferred Stock are entitled to receive dividend payments only when, as and if declared by the Board (or a duly authorized committee of the Board). The Series B Preferred Stock dividends will accrue or be payable in cash from the original issue date, on a cumulative basis, quarterly in arrears on each dividend payment date at a fixed rate per annum equal to 8.00% of the liquidation preference of $25.00 per share (equivalent to $2.00 per share on an annual basis). Dividends on the Series B Preferred Stock are cumulative and accrue whether or not (i) funds are legally available for the payment of those dividends, (ii) the Company has earnings or (iii) those dividends are declared by the Board. The Series B Preferred Stock may be partially or fully redeemed by the Company beginning in November 2030. The quarterly dividend payment dates on the Series B Preferred Stock are January 31, April 30, July 31 and October 31 of each year. During the six-month period ended June 30, 2026 the Company paid preferred dividends on its Series B Preferred Stock of $1,820. There were no Series B Preferred Stock shares issued and outstanding during the six-month period ended June 30, 2025.

-20-

Table of Contents

Series C Convertible Preferred Stock

On May 29, 2026 and June 2, 2026, the Company issued an aggregate of 1,000,000 shares of its Series C Convertible Preferred Stock, for aggregate gross proceeds of $100.0 million. The Series C Convertible Preferred Stock provides for cumulative dividends at a rate of 6.00% per annum, which increases to 8.00% on June 2, 2030 (the date that is four years after the date of last issuance) to the extent the Series C Convertible Preferred Stock is not redeemed or converted and increases by an additional 2.00% on each subsequent anniversary thereafter, up to a maximum of 12.00%, to the extent the Series C Convertible Preferred Stock is not redeemed or converted as of such anniversary dates. The Series C Convertible Preferred Stock is convertible into shares of the Company’s common stock at an initial conversion rate of 2.32558 shares of common stock per share of Series C Convertible Preferred Stock, which is based on an implied conversion price of $43.00 per share of common stock, subject to certain anti-dilution adjustments. The Company may redeem the Series C Convertible Preferred Stock, in whole or in part, at its option on or after June 2, 2030 (the date that is four years after the date of last issuance), at a cash redemption price equal to the liquidation preference of $100 per share, plus accumulated and unpaid regular dividends, including any defaulted regular dividends. The Series C Convertible Preferred Stock generally has no voting rights, except for limited voting rights with respect to certain matters affecting its rights and preferences. In addition, upon issuance of the Series C Convertible Preferred Stock, the Company’s ability to make distributions with respect to, or redeem, purchase or acquire, or make liquidation payments on, any other shares of capital stock ranking junior to or on a parity with the Series C Convertible Preferred Stock became subject to certain restrictions in the event that the Company does not declare distributions on the Series C Convertible Preferred Stock during any distribution period.

The Company assessed the characteristics of the Series C Convertible Preferred Stock in accordance with the provisions of ASC Topic 480 – “Distinguishing Liabilities from Equity,” and concluded that the Series C Convertible Preferred Stock is classified as permanent equity.

Series C Convertible Preferred Stock dividend activity for the six months ended June 30, 2026 is summarized in the following table:

  ​ ​ ​

  ​ ​ ​

  ​ ​ ​

Quarterly

  ​ ​ ​

Dividends

Date Announced

Record Date

Payment Date

Dividend (1)

per Share

N/A (2)

June 15, 2026

June 30, 2026

$

502

$

0.50

(1)Represents initial dividend from May 29, 2026 (with respect to 700,000 shares) and June 2, 2026 (with respect to 300,000 shares) through June 29, 2026.
(2)Because the Series C Convertible Preferred Stock is not publicly traded, no public announcement was made regarding this dividend.

Dividends on the Series C Convertible Preferred Stock are cumulative and accrue whether or not (i) funds are legally available for the payment of those dividends, (ii) the Company has earnings or (iii) those dividends are declared by the Board. The Series C Convertible Preferred Stock may not be redeemed by the Company prior to the applicable redemption trigger date and may thereafter be partially or fully redeemed by the Company for cash, subject to the terms of the Articles Supplementary related to the Series C Convertible Preferred Stock. The quarterly dividend payment dates on the Series C Convertible Preferred Stock are March 31, June 30, September 30 and December 31 of each year. During the six-month period ended June 30, 2026, the Company paid preferred dividends on its Series C Convertible Preferred Stock of $502. There were no Series C Convertible Preferred Stock shares issued and outstanding during the six-month period ended June 30, 2025.

Common Stock

The Company had 100,000,000 authorized shares of common stock, $0.001 par value and as of June 30, 2026 and December 31, 2025, there were 13,234,830 outstanding shares of common stock.

-21-

Table of Contents

Common stock dividend activity for the six months ended June 30, 2026 is summarized in the following table:

  ​ ​ ​

  ​ ​ ​

  ​ ​ ​

Dividend

  ​ ​ ​

Dividends

Date Announced

Record Date

Payment Date

Amount(1)(2)

per Share(3)

December 4, 2025

 

December 19, 2025

 

January 9, 2026

$

10,839

$

0.75

February 25, 2026

March 20, 2026

April 17, 2026

$

3,619

$

0.25

February 25, 2026

April 20, 2026

May 15, 2026

$

3,620

$

0.25

February 25, 2026

May 20, 2026

June 12, 2026

$

3,623

$

0.25

May 5, 2026

June 22, 2026

July 17, 2026

$

2,319

$

0.16

May 5, 2026

July 20, 2026

August 14, 2026

$

2,319

$

0.16

May 5, 2026

August 20, 2026

September 18, 2026

$

2,319

$

0.16

(1)Includes distributions on outstanding LTIP Units and OP Units.
(2)Dividend amounts for the July and August dividend record dates are estimated based on the outstanding shares of common stock and units as of June 30, 2026.
(3)On February 24, 2026, the Company’s Board of Directors approved a transition from a quarterly dividend to a monthly dividend. The dividend rate of $0.75 per share per quarter remained unchanged through the dividends paid on June 12, 2026. On May 5, 2026, the Company’s Board of Directors approved a monthly dividend of $0.16 for the dividends payable on July 17, 2026, August 14, 2026 and September 18, 2026.

During the six months ended June 30, 2026 and 2025, the Company paid total dividends on its common stock, LTIP Units and OP Units in the aggregate amount of $21,801 and $30,503, respectively.

As of June 30, 2026 and December 31, 2025, the Company had accrued dividend balances of $300 and $216 for dividends payable on the aggregate annual and long-term LTIP Units that are subject to retroactive receipt of dividends on the amount of LTIP Units ultimately earned. During the six months ended June 30, 2026, $184 dividends were accrued and $100 of dividends were paid related to these units. During the six months ended June 30, 2025, $156 of accrued dividends were reversed and $105 of dividends were paid related to these units.

The amount of the dividends paid to the Company’s stockholders is determined by the Board and is dependent on a number of factors, including funds available for payment of dividends, the Company’s financial condition and capital expenditure requirements, except that, in accordance with the Company’s organizational documents and Maryland law, the Company may not make dividend distributions that would: (i) cause it to be unable to pay its debts as they become due in the usual course of business; (ii) cause its total assets to be less than the sum of its total liabilities plus senior liquidation preferences; or (iii) jeopardize its ability to maintain its qualification as a REIT.

Capital Raising Activity

In January 2024, the Company and the Operating Partnership implemented a $300 million “at-the-market” equity offering program, pursuant to which the Company may offer and sell (including through forward sales), from time to time, shares of its common stock (the “2024 ATM Program”). No shares were sold under the 2024 ATM Program during the six months ended June 30, 2026. As of June 30, 2026, the Company has $288.0 million remaining available under the 2024 ATM Program.

In February 2026, the Company and the Operating Partnership implemented a $75 million “at-the-market” equity offering program, pursuant to which the Company may offer and sell (including through forward sales), from time-to-time, shares of its Series B Preferred Stock (the “2026 Series B Preferred ATM Program”). No shares were sold under the 2026 Series B Preferred ATM Program during the six months ended June 30, 2026.

On May 29, 2026 and June 2, 2026, the Company issued an aggregate of 1,000,000 shares of its Series C Convertible Preferred Stock in a private placement for aggregate gross proceeds of $100 million.

Common Stock Repurchase Program

In August 2025, the Board approved a $50 million common stock repurchase program (the “Stock Repurchase Program”). Under the Stock Repurchase Program, the Company may purchase up to $50 million of its outstanding shares of common stock from

-22-

Table of Contents

time to time in the open market, including through block purchases, through privately negotiated transactions or pursuant to any Rule 10b5-1 trading plan, in accordance with applicable securities laws. The specific timing, price and size of purchases will depend on prevailing stock prices, general economic and market conditions and other considerations. The Stock Repurchase Program does not obligate the Company to repurchase any dollar amount or number of shares of its common stock and may be suspended or discontinued at any time. No shares were repurchased during the six months ended June 30, 2026 and $44 million may yet be purchased under the Stock Repurchase Program. During the year ended December 31, 2025, 175,634 shares or approximately $6 million of the Company’s common stock were repurchased under the Stock Repurchase Program.

OP Units

During the six months ended June 30, 2026, the Operating Partnership did not issue or redeem any OP Units. During the year ended December 31, 2025, the Operating Partnership did not issue any OP Units and redeemed 5,000 OP Units (adjusted to reflect the impact of the Reverse Stock Split).

The OP Unit value at issuance and redemption is based on the Company’s closing share price on the date of the respective transaction and is included as a component of noncontrolling interest equity in the Company’s Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025. The Company has sufficient shares of common stock authorized pursuant to its charter to cover the redemption of outstanding OP Units.

Note 6 – Related Party Transactions

Related Party Balances

The amounts due from related parties as of June 30, 2026 and December 31, 2025 were $728 and $162, respectively. These balances primarily consist of receivables from the formation of our IRF Joint Venture, taxes paid on behalf of LTIP Unit and OP Unit holders that are reimbursable to the Company, as well as funds owed to the Company from the Heitman OM Joint Venture for management fees earned by the Company.

Note 7 – Stock-Based Compensation

2016 Equity Incentive Plan

The 2016 Equity Incentive Plan, as amended (the “Plan”), is intended to assist the Company and its affiliates in recruiting and retaining employees of the Company, members of the Board, executive officers of the Company, and individuals who provide services to the Company and its affiliates.

The Plan is intended to permit the grant of both qualified and non-qualified options and the grant of stock appreciation rights, restricted stock, unrestricted stock, awards of restricted stock units, performance awards and other equity-based awards (including LTIP Units). Based on the grants outstanding as of June 30, 2026, there were 455,627 shares of common stock that remain available to be granted under the Plan. Units subject to awards under the Plan that are forfeited, cancelled, lapsed, or otherwise expired (excluding shares withheld to satisfy exercise prices or tax withholding obligations) are available for grant.

Time-Based Grants

During the six months ended June 30, 2026, the Company granted the following LTIP Units:

Number of

Date

Description

Units Issued

February 24, 2026

Final awards under the 2025 Annual Incentive Plan

33,187

February 24, 2026

Time-based awards under the 2026 Long-Term Incentive Plan

63,626

(1)

April 1, 2026

Discretionary grant

2,237

May 20, 2026

Annual awards to independent directors

12,191

(1)Time-based awards under the 2026 Long-Term Incentive Plan vest upon the third anniversary of the respective grant dates. Vesting may be accelerated under certain circumstances such as a “change-in-control” transaction or a “qualified termination” event.

-23-

Table of Contents

A detail of the Company’s outstanding time-based LTIP Units as of June 30, 2026 is as follows:

Vested units

  ​ ​ ​

605,336

Unvested units

 

207,494

LTIP Units outstanding as of June 30, 2026

 

812,830

Performance Based Awards

The Board has approved annual performance-based LTIP awards (“Annual Awards”) and long-term performance-based LTIP awards (“Long-Term Awards” and together with the Annual Awards, “Performance Awards”) to the executive officers and other employees of the Company. As described below, the Annual Awards have one-year performance periods and the Long-Term Awards have three-year performance periods. In addition to meeting specified performance metrics, vesting in the Performance Awards is subject to service requirements.

A detail of the Performance Awards under the 2024, 2025 and 2026 programs as of June 30, 2026 is as follows:

2024 Long-Term Awards

 

38,531

2025 Long-Term Awards

32,944

2026 Annual Awards (1)

43,530

2026 Long-Term Awards (2)

60,134

Total target Performance Awards as of June 30, 2026

 

175,139

(1)Approved by the Board on February 24, 2026. The number of target LTIP Units was based on the average closing price of the Company’s common stock reported on the New York Stock Exchange over the 15 trading days preceding the award date.
(2)Approved by the Board on February 24, 2026. The number of target LTIP Units was based on the fair value of the Long-Term Awards as determined by an independent valuation consultant. See additional detail below.

Annual Awards. The Annual Awards are subject to the terms and conditions of LTIP Annual Award Agreements (“LTIP Annual Award Agreements”) between the Company and each grantee.

The Compensation Committee of the Board (the “Compensation Committee”) and the Board established performance goals for the year ending December 31, 2026, as set forth in the 2026 LTIP Annual Award Agreements (the “Performance Goals”) that will be used to determine the number of LTIP Units earned by each grantee. Cumulative stock-based compensation expense during the three and six months ended June 30, 2026 reflects management’s estimate of the probability of the number of these awards that will be earned. As soon as reasonably practicable following the end of the performance period, the Compensation Committee and the Board will determine the extent to which the Company has achieved each of the Performance Goals (expressed as a percentage) and, based on such determination, will calculate the number of LTIP Units that each grantee is entitled to receive. Each grantee may earn up to 150% of the number of his/her target LTIP Units. Any 2026 Annual Award LTIP Units that are not earned will be forfeited and cancelled.

Vesting. LTIP Units that are earned as of the end of the applicable performance period will vest in two installments as follows: 50% of the earned LTIP Units will become vested on the valuation date of the awards (which is expected to occur in February 2027) and 50% of the earned LTIP Units become vested on the one-year anniversary of the initial vesting date. Vesting may be accelerated under certain circumstances such as a “change-in-control” transaction or a “qualified termination” event.

Distributions. Distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the estimated number of LTIP Units that the grantee could earn and will be paid with respect to all of the earned LTIP Units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP Units at the discretion of the Compensation Committee.

Long-Term Awards. The Long-Term Awards are subject to the terms and conditions of their related LTIP Long-Term Award Agreements (collectively the “LTIP Long-Term Award Agreements”) between the Company and each grantee. The number of LTIP Units that each grantee earns under the LTIP Long-Term Award Agreements will be determined following the conclusion of a three-year performance period based on the Company’s (i) total stockholder return (“TSR”), which is determined based on a combination of appreciation in stock price and dividends paid during the performance period, and (ii) relative stockholder return (“RSR”), which is determined by comparing the Company’s TSR with the TSRs of the companies that comprise the Dow Jones U.S. Real Estate Health Care Index (the “Index”). Each grantee may earn up to 200% of the number of target LTIP Units covered by the grantee’s Long-Term

-24-

Table of Contents

Award. Any target LTIP Units that are not earned will be forfeited and cancelled. The number of LTIP Units earned under the Long-Term Awards will be determined as soon as reasonably practicable following the end of the applicable three-year performance period based on the Company’s TSR on an absolute basis (as to 50% of the Long-Term Award) and RSR (as to 50% of the Long-Term Award).

Vesting. LTIP Units that are earned as of the end of the applicable three-year performance period will vest in two installments as follows: 50% of the earned LTIP Units will vest upon the day prior to the third anniversary of the respective grant dates and the remaining 50% will vest on the one-year anniversary of the initial vesting date. Vesting may be accelerated under certain circumstances such as a “change-in-control” transaction or a “qualified termination” event.

Distributions. Pursuant to the LTIP Long-Term Award Agreements, distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the estimated number of LTIP Units that the grantee could earn and will be paid with respect to all of the earned LTIP Units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP Units at the discretion of the Compensation Committee.

Stock-Based Compensation Expense

Compensation expense for LTIP Unit grants, Annual Awards, and Long-Term Awards is based on the grant date fair value of the units/awards, with no subsequent remeasurement required.

As the Long-Term Awards involve market-based performance conditions, the Company utilizes a Monte Carlo simulation to provide a grant date fair value for expense recognition. The Monte Carlo simulation is a generally accepted statistical technique used, in this instance, to simulate a range of possible future stock prices for the Company and the members of the Index over the Performance Periods. The purpose of this modeling is to use a probabilistic approach for estimating the fair value of the performance share award.

The assumptions used in the Monte Carlo simulation include beginning average stock price, valuation date stock price, expected volatilities, correlation coefficients, risk-free rate of interest, and expected dividend yield. The beginning average stock price is the beginning average stock price for the Company and each member of the Index for the 15 trading days leading up to the grant date of the Long-Term Award. The valuation date stock price is the closing stock price of the Company and each of the peer companies in the Index on the grant dates of the Long-Term Awards. The expected volatilities are modeled using the historical volatilities for the Company and the members of the Index. The correlation coefficients are calculated using the same data as the historical volatilities. The risk-free rate of interest is taken from the U.S. Treasury website and relates to the expected life of the remaining performance period on valuation or revaluation. Lastly, the dividend yield assumption is 0.0%, which is mathematically equivalent to reinvesting dividends in the issuing entity, which is part of the Company’s award agreement assumptions.

Below are details regarding certain of the assumptions for the Long-Term Awards using Monte Carlo simulations:

2026 Long-Term

2025 Long-Term

2024 Long-Term

  ​ ​ ​

Awards

  ​ ​ ​

Awards

  ​ ​ ​

Awards

  ​ ​ ​

Fair value

$

36.96

$

46.60

$

46.85

 

Target awards

 

60,134

 

32,944

 

38,531

 

Volatility

 

32.31

%  

 

28.67

%  

 

28.12

%  

Risk-free rate

 

3.44

%  

 

4.00

%  

 

4.38

%  

Dividend assumption

 

reinvested

 

reinvested

 

reinvested

 

Expected term in years

 

3

 

3

 

3

 

The Company incurred stock compensation expense of $1,378 and $2,607 for the three and six months ended June 30, 2026, respectively, and $1,728 and $1,879 for the three and six months ended June 30, 2025, respectively, related to the grants awarded under the Plan. Compensation expense is included within “General and Administrative” expense in the Company’s Condensed Consolidated Statements of Operations.

As of June 30, 2026, total unamortized compensation expense related to these awards of approximately $8.9 million is expected to be recognized over a weighted average remaining period of 1.9 years.

-25-

Table of Contents

Note 8 – Leases

The Company operates as both a lessor and a lessee. As a lessor, the Company is required under ASC Topic 842 to account for leases using an approach that is substantially similar to ASC Topic 840’s guidance for operating leases and other leases such as sales-type leases and direct financing leases. In addition, ASC Topic 842 requires lessors to capitalize and amortize only incremental direct leasing costs. As a lessee, the Company is required under the new standard to apply a dual approach, classifying leases, such as ground leases, as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC Topic 842 also requires lessees to record a right of use asset and a lease liability for all leases with an initial term of greater than a year regardless of their classification. The Company has also elected the practical expedient not to recognize right of use assets and lease liabilities for leases with a term of a year or less.

Information as Lessor

To generate positive cash flow, as a lessor, the Company leases its facilities to tenants in exchange for fixed monthly payments that cover rent, property taxes, insurance and certain cost recoveries, primarily common area maintenance (“CAM”). The Company’s leases are typically operating leases and generally have initial terms of approximately 5 to 15 years. Payments from the Company’s tenants for CAM are considered nonlease components that are separated from lease components and are generally accounted for in accordance with the revenue recognition standard. However, the Company qualified for and elected the practical expedient related to combining the components because the lease component is classified as an operating lease and the timing and pattern of transfer of CAM income, which is not the predominant component, is the same as the lease component, for all asset classes. As such, consideration for CAM is accounted for as part of the overall consideration in the lease. Payments from customers for property taxes and insurance are considered non-components of the lease and therefore no consideration is allocated to them because they do not transfer a good or service to the customer. Fixed contractual payments from the Company’s leases are recognized on a straight-line basis over the terms of the respective leases. This means that, with respect to a particular lease, actual amounts billed in accordance with the lease during any given period may be higher or lower than the amount of rental revenue recognized for the period. Straight-line rental revenue is commenced when the tenant assumes control of the leased premises. Accrued straight-line rents receivable represents the amount by which straight-line rental revenue exceeds rents currently billed in accordance with lease agreements.

Some of the Company’s leases are subject to annual changes in the Consumer Price Index (“CPI”). Although increases in CPI are not estimated as part of the Company’s measurement of straight-line rental revenue, for leases with base rent increases based on CPI, the amount of rent revenue recognized is adjusted in the period the changes in CPI are measured and effective. Additionally, some of the Company’s leases have extension options.

Initial direct costs, primarily commissions related to the leasing of our facilities are capitalized when material as incurred. Capitalized leasing costs are amortized on a straight-line basis over the remaining useful life of the respective leases. All other costs to negotiate or arrange a lease are expensed as incurred.

Lease-related receivables, which include accounts receivable and accrued straight-line rents receivable, are reduced for credit losses, if applicable. The Company regularly evaluates the collectability of its lease-related receivables. The Company’s evaluation of collectability primarily consists of reviewing past due account balances and considering such factors as the credit quality of our tenant, historical trends of the tenant and changes in tenant payment terms. If the Company’s assumptions regarding the collectability of lease-related receivables prove incorrect, the Company could experience credit losses in excess of what was recognized in rental and other revenues.

The Company recognized $37,060 and $75,081 of rental revenue related to operating lease payments for the three and six months ended June 30, 2026, respectively, and $37,880 and $72,475 of rental revenue related to operating lease payments for the three and six months ended June 30, 2025, respectively. Of these amounts, $1,596 and $3,188 relate to variable rental revenue for the three and six months ended June 30, 2026, respectively, and $2,028 and $3,821 relate to variable rental revenue for the three and six months ended June 30, 2025, respectively.

-26-

Table of Contents

The aggregate annual cash to be received by the Company on the noncancelable operating leases related to its portfolio as of June 30, 2026 is as follows for the subsequent years ended December 31:

2026 (six months remaining)

  ​ ​ ​

$

52,623

2027

 

97,583

2028

 

87,893

2029

 

73,305

2030

51,814

Thereafter

 

161,231

Total

$

524,449

Information as Lessee

As of June 30, 2026, the Company has 12 buildings located on land that is subject to ground leases with a weighted average remaining term of approximately 43 years. Rental payments on these leases are adjusted periodically based on either the CPI or on a pre-determined schedule. The monthly payments on a pre-determined schedule are recognized on a straight-line basis over the terms of the respective leases. Changes in the CPI are not estimated as part of our measurement of straight-line rental expense. Some of the Company’s ground leases contain extension options and, where we determined it was reasonably certain that an extension would occur, they were included in our calculation of the right of use asset and liability. The Company recognized approximately $100 and $200 of ground lease expense during the three and six months ended June 30, 2026, respectively, of which $72 and $158 was paid in cash. The Company recognized approximately $95 and $156 of ground lease expense during the three and six months ended June 30, 2025, respectively, of which $89 and $135 was paid in cash. The Company incurred interest expense of $68 and $134 from ground leases that were classified as financing leases for the three and six months ended June 30, 2026, respectively, and $69 from ground leases that were classified as financing leases for the three and six months ended June 30, 2025.

The following table sets forth the undiscounted cash flows of our scheduled obligations for future lease payments on operating ground leases at June 30, 2026, and a reconciliation of those cash flows to the operating lease liability at June 30, 2026:

2026 (six months remaining)

  ​ ​ ​

$

599

2027

 

1,212

2028

 

1,220

2029

 

1,239

2030

1,211

Thereafter

 

25,988

Total

31,469

Discount

 

(18,076)

Lease liability

$

13,393

Tenant Concentration

During the six months ended June 30, 2026, the Company’s rental revenues were derived from 182 healthcare facilities, primarily outpatient medical facilities, and 2 SHOP communities with no single tenant or resident exceeding 10% of the Company’s rental revenue.

Note 9 – Commitments and Contingencies

Litigation

The Company is not presently subject to any material litigation nor, to its knowledge, is any material litigation threatened against the Company, which if determined unfavorably to the Company, would have a material adverse effect on the Company’s financial position, results of operations, or cash flows.

Environmental Matters

The Company follows a policy of monitoring its properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at its properties, the Company is not currently aware of any

-27-

Table of Contents

environmental liability with respect to its properties that would have a material effect on its financial position, results of operations, or cash flows. Additionally, the Company is not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability that management believes would require additional disclosure or the recording of a loss contingency.

Note 10 – Segment Information

The Company operates its business through two reportable segments: Healthcare Real Estate and SHOP. The Healthcare Real Estate segment consists of the Company's outpatient medical buildings and other healthcare properties, which are aggregated in accordance with ASC 280-10-50-11 based on similar economic characteristics, comparable long-term financial performance, and shared operating attributes including lease-based revenue streams (accounted for under ASC 842), similar tenant customer bases and regulatory environments, and consistent capital allocation approaches. The SHOP segment consists of seniors housing communities operated by third-party managers under RIDEA-compliant management agreements pursuant to which the Company (through one or more taxable REIT subsidiaries) recognizes the operating results of the communities as resident fees and services under ASC 606. The Company has one seniors housing operating property that is not structured under a RIDEA arrangement. This property is held through a taxable REIT subsidiary, or TRS, which manages the property, and the property is sub-managed by an eligible independent contractor.

The Company's CODM is its Chief Executive Officer. The CODM evaluates the operating performance of the Company's reportable segments and makes resource allocation decisions based primarily on Segment Net Operating Income ("Segment NOI"). Segment NOI is defined as total segment revenues less property-level operating expenses attributable to the segment. Segment NOI excludes general and administrative expenses, depreciation and amortization, interest expense, gains and losses on sales of real estate, transaction-related costs, impairments, and other corporate-level or non-property-level items.

The composition of the Company's reportable segments changed during the period ended June 30, 2026 to reflect the Company's strategic transition to seniors housing. The Company did not have a SHOP segment during the 2025 periods presented; accordingly, the 2025 SHOP amounts presented below reflect no activity.

Total assets by reportable business segment and segment-level significant expense categories are not disclosed as our CODM is not provided with such information to evaluate business performance and allocate resources.

Segment NOI by Reportable Segment and Reconciliation to Consolidated Net Income

Summary information by reportable segment for the three and six months ended June 30, 2026 is as follows (unaudited, in thousands):

Three Months Ended June 30, 2026

(in thousands)

Healthcare Real Estate

SHOP

Total

Revenues:

Rental revenue

$

37,060

$

-

$

37,060

Resident fees and services

-

1,841

1,841

Other income

846

-

846

Total revenues

$

37,906

$

1,841

$

39,747

-

Property level expenses

(8,459)

(1,575)

(10,034)

NOI

$

29,447

$

266

$

29,713

General and administrative expenses

(5,221)

Depreciation expense

(11,443)

Amortization expense

(3,833)

Interest expense, net

(8,806)

Gain on sale of real estate, net

71,881

Equity in earnings of unconsolidated joint ventures

(10)

Consolidated income

$

72,281

-28-

Table of Contents

Six Months Ended June 30, 2026

(in thousands)

Healthcare Real Estate

SHOP

Total

Revenues:

Rental revenue

$

75,081

$

-

$

75,081

Resident fees and services

-

1,841

1,841

Other income

889

-

889

Total revenues

$

75,970

$

1,841

$

77,811

-

Property level expenses

(17,709)

(1,575)

(19,284)

NOI

$

58,261

$

266

$

58,527

General and administrative expenses

(10,310)

Depreciation expense

(22,530)

Amortization expense

(7,573)

Interest expense, net

(16,039)

Gain on sale of real estate, net

71,881

Equity in earnings of unconsolidated joint ventures

(21)

Consolidated income

$

73,935

Summary information by reportable segment for the three and six months ended June 30, 2025 is as follows (unaudited, in thousands):

Three Months Ended June 30, 2025

(in thousands)

Healthcare Real Estate

SHOP

Total

Revenues:

Rental revenue

$

37,880

$

-

$

37,880

Resident fees and services

-

-

-

Other income

89

-

89

Total revenues

$

37,969

$

-

$

37,969

-

Property level expenses

(8,216)

-

(8,216)

NOI

$

29,753

$

-

$

29,753

General and administrative expenses

(6,025)

Depreciation expense

(11,307)

Amortization expense

(3,984)

Interest expense, net

(8,009)

Gain on sale of real estate, net

207

Equity in earnings of unconsolidated joint ventures

(50)

Consolidated income

$

585

-29-

Table of Contents

Six Months Ended June 30, 2025

(in thousands)

Healthcare Real Estate

SHOP

Total

Revenues:

Rental revenue

$

72,475

$

-

$

72,475

Resident fees and services

-

-

-

Other income

112

-

112

Total revenues

$

72,587

$

-

$

72,587

-

Property level expenses

(15,800)

-

(15,800)

NOI

$

56,787

$

-

$

56,787

General and administrative expenses

(9,645)

Depreciation expense

(21,614)

Amortization expense

(7,504)

Interest expense, net

(15,176)

Gain on sale of real estate, net

1,565

Equity in earnings of unconsolidated joint ventures

(91)

Consolidated income

$

4,322

Concentration of Revenue

For the three and six months ended June 30, 2026, properties managed by Greystone Communities represented 100% of SHOP segment revenues. No other single tenant, operator, or manager represented 10% or more of consolidated total revenues for the periods presented.

All of the Company's revenues for each of the periods presented were derived from properties located in the United States.

Note 11 – Income Taxes

The Company qualifies as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended. As such, the Company is generally not taxed on income that is distributed to its stockholders.

Under RIDEA, a REIT may lease a "qualified healthcare property" on an arm's-length basis to a TRS if the property is operated on behalf of such TRS by a person who qualifies as an “eligible independent operator.” Generally, the rent received from the TRS will meet the related party exception and will be treated as “rents from real property.” A "qualified healthcare property" includes real property and any personal property that is, or is necessary or incidental to the use of, a hospital, nursing facility, assisted living facility, congregate care facility, qualified continuing care facility, or other licensed facility which extends medical or nursing or ancillary services to patients. The Company owns one IL facility that is operated as a SHOP asset but is not structured under a RIDEA arrangement. The facility is managed by a TRS and the TRS has engaged an eligible independent contractor to sub-manage the facility. Income generated by the TRS is subject to federal and state income taxes, as applicable.

Resident fees and services revenue and related operating expenses for the Company’s RIDEA properties are reported on its Consolidated Statements of Income and are subject to federal, state and local income taxes. For the Company’s non-RIDEA SHOP asset, the applicable TRS earns a management fee in connection with its management of the facility and pays a sub-management fee to an eligible independent contractor that sub-manages the facility. Taxable income of the TRS is subject to federal and state income taxes, as applicable.

Our provision for income taxes for the three and six months ended June 30, 2026 was insignificant.

Note 12 – Subsequent Events

On July 10, 2026, the Company entered into a purchase agreement with SSL to acquire a parcel of land located in Reston, Virginia (the “Reston Land Parcel”) for a purchase price of approximately $15.0 million. The Company expects that a seniors housing community will be developed on the land. The acquisition remains subject to customary closing conditions and is expected to close in August 2026.

-30-

Table of Contents

On July 16, 2026, the Company appointed Aaron Roseth as its Chief Operating Officer and Robert Zeiller as its Chief Development Officer and Head of Seniors Housing. Prior to joining the Company, Mr. Zeiller served as Chief Executive Officer of SSL, affiliates of which (i) were the managing member of the seller of the Landing and Riviera communities and (ii) are the managing member of the seller of (a) the Pinnacle North Bethesda community and (b) the Reston Land Parcel, both of which the Company is currently under contract to acquire. Mr. Zeiller has a consulting agreement (through December 31, 2026) with, is a director of and retains a minority ownership interest in SSL. As a result of Mr. Zeiller’s appointment and continuing relationship with SSL, the Company considers SSL and the applicable property transactions to be related party relationships beginning on July 16, 2026. In connection with these appointments, Danica Holley, the Company's former Chief Operating Officer, has been appointed Chief Administrative Officer.

On July 28, 2026, the Company originated an approximately $2.2 million mezzanine loan secured by interests in an entity that owns an under-development medical facility in Daleville, Virginia. The medical facility is a two-story, approximately 40,000 square foot freestanding emergency department and medical office building that is 100% pre-leased to an investment-grade regional healthcare system under a 15-year lease. The loan bears interest at 12% per annum, has an initial term of 24-month and included a 2.0% origination fee, with completion and repayment supported by a corporate guaranty. In connection with the loan, the Company holds a right of first offer and right of first refusal with respect to a sale of the property, which are subject to the pre-leased tenant’s corresponding rights.

On August 3, 2026, the Company entered into an agreement to sell its surgical hospital in Beaumont, Texas for approximately $49 million to an affiliate of a Delaware statutory trust (“DST”). The Company expects to receive proceeds from the sale as beneficial interests in the DST are sold to investors.

On August 3, 2026, the Company appointed Matthew Whitlock as its Chief Investment Officer. Mr. Whitlock will lead the Company's investment activities, with responsibility for sourcing, structuring, and executing senior housing investments, cultivating strategic partnerships, and helping guide the continued growth of Chiron's senior housing platform. In connection with Mr. Whitlock's appointment, the Company's former Chief Investment Officer, Alfonzo Leon, has transitioned to the role of Strategic Advisor through December 31, 2026.

There can be no assurance that acquisitions or dispositions will be completed on the anticipated timeline or at all.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our financial statements, including the notes to those financial statements, included elsewhere in this Quarterly Report on Form 10-Q (this “Report”). Some of the statements we make in this section are forward-looking statements within the meaning of the federal securities laws. For a complete discussion of forward-looking statements, see the section below entitled “Special Note Regarding Forward-Looking Statements.” Certain risk factors may cause actual results, performance, or achievements to differ materially from those expressed or implied by the following discussion. For a discussion of such risk factors, see Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Annual Report”), that was filed with the U.S. Securities and Exchange Commission (the “SEC” or the “Commission”) on March 2, 2026 and Item 1A. Risk Factors in this Quarterly Report on Form 10-Q. Unless otherwise indicated, all dollar amounts in the following discussion are presented in thousands.

Special Note Regarding Forward-Looking Statements

This Report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). In particular, statements pertaining to our trends, liquidity, capital resources, future dividends, pending acquisitions, potential sales, the healthcare industry, the healthcare real estate markets and seniors housing opportunities, among others, contain forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology including, but not limited to, “believes,” “expects,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates” or “anticipates” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen

-31-

Table of Contents

at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

difficulties in identifying healthcare and seniors housing facilities to acquire (due to increased cost of capital, competition or otherwise) and completing such acquisitions;
defaults on or non-renewal of leases by tenants;
our ability to collect rents;
increases in interest rates and increased operating costs;
our operating assets in our SHOP segment may expose us to various operational risks, liabilities and claims;
our ability to renew our management agreements with our SHOP managers on as favorable terms or at all, and our ability when necessary, to effectively and efficiently transition a SHOP community to a new manager;
our ability to successfully re-align our portfolio in connection with the expansion of our investment strategy to focus primarily on seniors housing properties;
macroeconomic and geopolitical factors, including, but not limited to, inflationary pressures, tariffs and international trade policies, elevated interest rates, distress in the banking sector, global supply chain disruptions and ongoing geopolitical conflicts and war;
changes in current healthcare and healthcare real estate trends and costs, including wage inflation;
an epidemic or pandemic (such as the COVID-19 epidemic), and the measures that international, federal, state and local governments, agencies, law enforcement and/or health authorities implement to address it;
our ability to satisfy the covenants in our existing and any future debt agreements;
our ability to refinance our existing debt when needed or on favorable terms;
decreased rental rates or increased vacancy rates, including expected rent levels on acquired properties;
adverse economic or real estate conditions or developments, either nationally or in the markets in which our facilities are located;
our failure to generate sufficient cash flows to service our outstanding obligations;
our ability to satisfy our short and long-term liquidity requirements;
our ability to deploy the debt and equity capital we raise;
our ability to hedge our interest rate risk;
our ability to raise additional equity and debt capital on attractive terms or at all;
our ability to make distributions on shares of our common and preferred stock or to redeem our preferred stock;
expectations regarding the timing and/or completion of any acquisition;
expectations regarding the timing and/or completion of dispositions, and the expected use of proceeds therefrom;
our use of joint ventures may limit our returns on and our flexibility with jointly-owned investments;
general volatility of the market price of our common and preferred stock;

-32-

Table of Contents

changes in our business or our investment or financing strategy;
our dependence upon key personnel, whose continued service is not guaranteed;
our ability to identify, hire and retain highly qualified personnel in the future;
the degree and nature of our competition;
changes in healthcare laws, governmental regulations, tax laws and similar matters;
changes in expected trends in Medicare, Medicaid and commercial insurance reimbursement trends, including changes in Medicaid reimbursement rates pursuant to the One Big Beautiful Bill Act (the “OBBBA”);
competition for investment opportunities;
our failure to achieve the anticipated benefits from, and effectively integrate, our completed or anticipated acquisitions and investments;
our expected capital and tenant improvement expenditures;
changes in accounting policies generally accepted in the United States of America (“GAAP”);
lack of, or insufficient amounts of, insurance;
other factors affecting the real estate industry generally;
changes in the tax treatment of our distributions;
our failure to maintain our qualification as a real estate investment trust (“REIT”) for U.S. federal income tax purposes;
our ability to qualify for the safe harbor from the 100% prohibited transactions tax under the REIT rules with respect to our property dispositions; and
limitations imposed on our business due to, and our ability to satisfy, complex rules relating to REIT qualification for U.S. federal income tax purposes.

See Item 1A. Risk Factors in our 2025 Annual Report and Item 1A. Risk Factors in this Quarterly Report on Form 10-Q for further discussion of these and other risks, as well as the risks, uncertainties and other factors discussed in this Report and identified in other documents we may file with the SEC from time to time. You should carefully consider these risks before making any investment decisions in our company. New risks and uncertainties may also emerge from time to time that could materially and adversely affect us. While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes after the date of this Report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements.

Overview

Chiron Real Estate Inc. (the “Company”) is a Maryland corporation and internally managed real estate investment trust (“REIT”) that owns (i) healthcare facilities leased to physician groups and regional and national healthcare systems and (ii) seniors housing communities. The Company’s seniors housing includes independent living communities (“IL”), assisted living communities (“AL”), memory care communities (“MC”) and active adult communities. As of June 30, 2026, the Company’s total gross investment portfolio consisted of 82% healthcare facilities, primarily outpatient medical facilities, 16% seniors housing operating portfolio (“SHOP”) assets, and 2% unconsolidated joint ventures and other investments.

-33-

Table of Contents

The Company holds its facilities and conducts its operations through a Delaware limited partnership subsidiary, Chiron Real Estate LP (the “Operating Partnership”). The Company serves as the sole general partner of the Operating Partnership through a wholly owned subsidiary of the Company, Chiron Real Estate GP LLC, a Delaware limited liability company. As of June 30, 2026, the Company owned 91.3% of the outstanding common operating partnership units (“OP Units”), with the remaining 8.7% owned by holders of long-term incentive plan units (“LTIP Units”) and third-party limited partners who contributed properties or services in exchange for OP Units.

Our revenues are derived from the rental and operating expense reimbursement payments we receive from our tenants, and most of our leases are medium to long-term triple net leases with contractual rent escalation provisions. We also derive revenue from resident agreements at our SHOP communities. Our primary expenses are depreciation, interest, property operating and general and administrative expenses. We finance our acquisitions with a mixture of debt and equity primarily from our cash from operations, borrowings under our Credit Facility, and stock issuances.

On September 19, 2025, the Company completed a one-for-five reverse stock split of its outstanding shares of common stock, with a corresponding adjustment to the outstanding partnership units of the Operating Partnership (the “Reverse Stock Split”). Unless otherwise noted, all common share and unit amounts shown herein are shown on a split-adjusted basis.

Business Overview and Strategy

We have expanded our business strategy to focus primarily on investments in seniors housing communities that provide an attractive rate of return relative to our cost of capital and are in attractive markets with favorable demographic trends. We believe these asset classes are well positioned to benefit from the growing needs of an aging population and support our goals of providing stockholders with (i) attractive dividends and (ii) stock price appreciation. We are focused on transitioning our asset base from one historically concentrated in outpatient medical facilities to one more heavily weighted toward seniors housing communities.

We also intend to utilize our experience and knowledge of inpatient rehabilitation facilities and outpatient medical real estate to manage our existing joint ventures and to evaluate healthcare real estate opportunities that complement our seniors housing strategy.

Most of our legacy healthcare facilities are leased to single tenants under triple-net leases. Our portfolio also contains some multi-tenant properties with gross lease or modified gross lease structures. In addition, we own SHOP communities from which we derive revenue from resident agreements. As of June 30, 2026, we also had an interest in four unconsolidated joint ventures that own or are developing healthcare and active adult facilities.

Our Properties

As of June 30, 2026, we had gross investments of approximately $1.6 billion in real estate, consisting of 182 healthcare facilities, primarily outpatient medical facilities, with an aggregate of approximately 4.6 million leasable square feet, and 2 SHOP communities, with an aggregate of 292 homes. This data does not include amounts for properties held in our unconsolidated joint ventures.

2026 Investment Activity

Acquired Properties

On June 1, 2026, the Company completed the acquisition of The Landing Alexandria (the “Landing”), a 163-home, luxury seniors housing community located in Alexandria, Virginia, from affiliates of Silverstone Senior Living (“SSL”) for a purchase price of approximately $130 million. The Landing has operated since May 2022 and offers independent living, assisted living and memory care.

On June 1, 2026, the Company completed the acquisition of The Riviera at Alexandria (the “Riviera”), a 129-home, luxury seniors housing community located in Alexandria, Virginia, from affiliates of SSL for a purchase price of approximately $119 million. The Riviera is a newly developed independent living community that opened in March 2026 and remains in lease-up.

The Company operates the Landing and the Riviera as SHOP communities and one of its taxable REIT subsidiaries (“TRS”) has engaged an affiliate of Greystone Communities to manage the day-to-day operations of the communities. Under this structure, the

-34-

Table of Contents

Company owns the real estate and participates directly in the operating results of the communities, including revenues and operating expenses, rather than receiving fixed lease payments from a third-party tenant.

Properties Under Contract

On May 6, 2026, the Company entered into an agreement to acquire The Pinnacle North Bethesda (the “Pinnacle”), a newly constructed luxury senior housing community located in North Bethesda, Maryland, from an affiliate of SSL for a purchase price of approximately $176 million, subject to customary closing conditions and purchase price adjustments. The Pinnacle is expected to contain 175 homes, including independent living, assisted living, and memory care homes, together with ground floor retail. The closing of the Pinnacle acquisition is expected to occur on or before October 2026, subject to the satisfaction or waiver of customary closing conditions.

On July 10, 2026, the Company entered into a purchase agreement with SSL to acquire a parcel of land located in Reston, Virginia for a purchase price of approximately $15.0 million. The Company expects that a seniors housing community will be developed on the land. The acquisition remains subject to customary closing conditions and is expected to close in August 2026.

On August 3, 2026, the Company entered into an agreement to sell its surgical hospital in Beaumont, Texas for approximately $49 million to an affiliate of a Delaware statutory trust (“DST”). The Company expects to receive proceeds from the sale as beneficial interests in the DST are sold to investors.

There can be no assurance that acquisitions or dispositions will be completed on the anticipated timeline or at all.

Joint Ventures

On January 6, 2026, the Company entered into a joint venture with a developer to facilitate the development of a 132-home, active adult residential community in a suburb of Minneapolis, Minnesota (the “Maple Grove Active Adult Joint Venture”). We invested $7.1 million for a 49% equity interest in the Maple Grove Active Adult Joint Venture, with the developer retaining a 51% interest. The Maple Grove Active Adult Joint Venture entered into a construction loan with a principal balance of $31.0 million, of which $10.1 million was drawn on as of June 30, 2026. The developer is serving as the managing member of the Maple Grove Active Adult Joint Venture. We account for our interest in the Maple Grove Active Adult Joint Venture using the equity method of accounting.

On May 13, 2026, the Company entered into a joint venture with a developer to facilitate the development of an active adult residential community near Hudson, Wisconsin (the “Hudson Active Adult Joint Venture”). We invested $6.7 million for a 49% equity interest, with the developer retaining a 51% interest and serving as the managing member. We account for our interest in the Hudson Active Adult Joint Venture using the equity method of accounting.

On June 10, 2026, the Heitman OM Joint Venture acquired an additional medical office building located near Minneapolis, Minnesota, for a purchase price of $10.3 million, with the Company contributing its 12.5% proportionate share of the purchase price in accordance with the joint venture agreement. The Heitman OM Joint Venture has obtained two mortgage loans with a total principal balance of $22.9 million.

On June 29, 2026, the Company completed the sale of seven inpatient rehabilitation facilities (“IRFs”) to a newly formed joint venture (the “IRF Joint Venture”) between the Company, through its Operating Partnership, and a U.S. public pension fund (the “IRF JV Partner”). The portfolio was valued at an aggregate purchase price of $217 million and comprised approximately 456,000 square feet of space that was 100% leased with a weighted average remaining lease term of eight years. In connection with the transaction, the Company received net proceeds of $211.4 million, before funding its $16.3 million retained equity investment in the IRF Joint Venture, and recognized a gain on the sale of investment properties of $71.9 million. The IRF JV Partner acquired an 85% equity interest and controls the IRF Joint Venture through its voting interest, while the Company acquired a 15% equity interest, serves as manager of the joint venture, and continues to oversee asset management in exchange for a management fee. The IRF Joint Venture obtained a mortgage loan with a principal balance of $108.5 million, and the Company accounts for its retained interest using the equity method of accounting.

Real Estate Loans

On April 1, 2026, the Company originated a $3.0 million mezzanine loan secured by interests in an entity that owns an under-development medical facility located in Fort Myers, Florida, of which $2.9 million was drawn as of June 30, 2026. The medical facility is an on-campus outpatient surgical facility that is 100% pre-leased to an investment-grade tenant under a 15-year lease. The loan bears interest at a rate of 12.0% per annum and has an initial term of 24 months and included a 2.0% origination fee, with completion and

-35-

Table of Contents

repayment supported by a corporate guaranty. In connection with the loan, the Company holds a right of first offer and right of first refusal with respect to a sale of the property, which are subject to the pre-leased tenant’s corresponding rights.

On July 28, 2026, the Company originated an approximately $2.2 million mezzanine loan secured by interests in an entity that owns an under-development medical facility in Daleville, Virginia. The medical facility is a two-story, approximately 40,000 square foot freestanding emergency department and medical office building that is 100% pre-leased to an investment-grade regional healthcare system under a 15-year lease. The loan bears interest at 12% per annum, has an initial term of 24-month and included a 2.0% origination fee, with completion and repayment supported by a corporate guaranty. In connection with the loan, the Company holds a right of first offer and right of first refusal with respect to a sale of the property, which are subject to the pre-leased tenant’s corresponding rights.

2026 Disposition Activity

On June 29, 2026, the Company disposed of certain properties in connection with its investment activity, including the sale of seven IRFs to the IRF Joint Venture described above under “Joint Ventures.”

Recent Developments

On January 20, 2026, White Rock Medical Center LLC, filed for Chapter 11 bankruptcy protection under the United States Bankruptcy Code. At the time of its bankruptcy filing, White Rock operated two hospitals in Texas, including the White Rock Medical Center in Dallas, Texas, an acute-care hospital owned by the Company where White Rock is the sole tenant and has been operating the hospital since October 2023. There are 12 years remaining on this lease. According to the filed bankruptcy documents, the primary reason for the bankruptcy is a dispute with the former operator of the facility related to amounts due to the former operator. Accordingly White Rock plans to (i) restructure indebtedness related to its purchase of the hospital operations at the White Rock Medical Center and a related transition services agreement and (ii) sell its hospital operations to a third party, with the goal of stabilizing its operations and maximizing value to its stakeholders. As a means of assisting White Rock in its stabilization efforts, the Company has funded annual property tax obligations due under the lease and accepted reduced monthly payments. As of August 3, 2026, the Company has a receivable balance, net of security deposits, of approximately $1.7 million (exclusive of late fees and interest thereon). On July 10, 2026, White Rock filed its Second Plan of Reorganization where it indicated that it plans on affirming our lease as part of its reorganization plan. Although White Rock indicated that it intends on affirming our lease, there can be no assurance that White Rock will not change its plan to affirm its lease with us or that we will receive any amounts owed to us.

Trends Which May Influence Our Results of Operations

We believe the following trends may positively impact our results of operations:

An aging population. The general aging of the population, driven by the large baby boomer generation (born 1946-1964) and increases in life expectancy due to advances in medical technology and services, continues to be a key driver of growth in healthcare expenditures. According to the most recent U.S. Census Bureau estimates, the population age 65 and older grew by over a third during the past decade, and roughly 3.1% from 2023 to 2024 and is projected to continue growing at a rate that exceeds that of the overall U.S. population. We believe this segment of the U.S. population will utilize many of the services provided at our healthcare facilities, including orthopedics, cardiovascular, gastroenterology and rehabilitation services.

Seniors housing communities. As occupancy continues to recover in many markets and new supply remains constrained, owners of seniors housing properties have generally seen improving profitability and greater pricing power, including the ability to increase resident fees and reduce concessions. Margin recovery remains influenced by labor availability and wage pressure, as well as elevated insurance and other operating costs; accordingly, community performance tends to be strongest at well-located assets with experienced operators and favorable payer/resident mix.

A continuing shift towards outpatient care. According to the American Hospital Association, patients are demanding more outpatient operations. We believe this shift in patient preference from inpatient to outpatient facilities will benefit our tenants as most of our properties consist of outpatient facilities.

Physician practice group and hospital consolidation. We believe the trend towards physician group consolidation will serve to strengthen the credit quality of our tenants if our tenants merge or are consolidated with larger health systems.

-36-

Table of Contents

We believe the following trends may negatively impact our results of operations:

Interest rates remain at elevated levels. During 2025, the U.S. Federal Reserve (the “Fed”) continued lowering the Federal Funds Rate, with the most recent reduction in December 2025 bringing the target range to 3.50% to 3.75%, where it remained through June 30, 2026. During the first six months of 2026, the 10-year U.S. Treasury yield and the Secured Overnight Financing Rate (“SOFR”) increased modestly. As of June 30, 2026 the 10-year U.S. Treasury yield was 4.44% and one-month term SOFR was 3.63%.

Although interest rates declined during 2025, they remain significantly higher than in 2021, when we entered into interest rate swaps with respect to the $350 million Term Loan A component of our Credit Facility. Those swaps fixed the SOFR component of the interest rate on Term Loan A at 1.36% and expired in April 2026, the original maturity date of Term Loan A. In connection with the extension and restructuring of Term Loan A, we entered into new interest rate swaps that fully hedge the SOFR components of the three new Term Loan A tranches through their respective maturities at fixed SOFR rates ranging from 3.24% to 3.32%. The current elevated interest rate environment has resulted in material increases in our interest expense with respect to our unhedged floating-rate indebtedness and, beginning in May 2026, increased our interest expense on the hedged Term Loan A tranches due to the higher fixed SOFR rates under the new swaps.

Labor and wage pressure.  Assisted living wage rates continued to rise in 2025 across nursing and direct-care roles. The Assisted Living Salary & Benefits Report cited by Senior Housing News reported 2025 hourly wage increases of approximately 2.96% for registered nurses, 2.77% for certified nursing assistants, 2.98% for resident assistants and 3.15% for medication aides. It also reported assisted living turnover of 34.53%, with resident assistant and personal care aide turnover above 40%.

Increased Cost of Healthcare Delivery. Healthcare delivery costs continue to increase due to, among other things, increases in labor costs, medical supplies and technology investments. Increases in the cost of healthcare delivery can put stress on our tenants’ business, which, if not offset by revenue increases, could negatively affect our tenants’ ability to pay rent to us.

Changes in third party reimbursement methods and policies. The price of healthcare services has been increasing, and, as a result, we believe that third-party payors, such as Medicare and commercial insurance companies, will continue to scrutinize and reduce the types of healthcare services eligible for, and the amounts of, reimbursement under their health insurance plans or increase the portion of premiums for which covered individuals are responsible. In January 2026, CMS announced proposed rate increases for 2027 to Medicare Advantage health plans of less than a tenth of a percent, which was less than market expectations. However, in April 2026, CMS finalized a net average increase of approximately 2.5%, representing more than $13 billion of additional payments to Medicare Advantage plans compared to 2026. While the final rate increase was significantly higher than initially proposed, reimbursement pressure on healthcare providers and payors remains a continuing industry concern. Additionally, beginning on January 1, 2026, premium tax credits that were intended to assist certain participants on the healthcare insurance exchanges in purchasing health insurance expired, which could result in significant premium increases for these participants. If these trends continue, our tenants’ businesses will continue to be negatively affected, which may impact their ability to pay rent to us.

Critical Accounting Estimates

The preparation of financial statements in conformity with GAAP requires our management to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Please refer to our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 2, 2026, for further information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our condensed consolidated financial statements included in Part I, Item 1 of this Report.

-37-

Table of Contents

Segment Results

Beginning June 1, 2026, we operate through two reportable segments: Healthcare Real Estate and SHOP. Healthcare Real Estate continues to represent the majority of our revenues and Segment NOI for the three and six months ended June 30, 2026. SHOP results reflect one month of operations from the Landing and the Riviera following their acquisition on June 1, 2026. SHOP Segment NOI was $0.3 million for both the three and six months ended June 30, 2026, reflecting the partial-period contribution from these communities. We expect SHOP to become a more significant component of our results as recently acquired communities stabilize and as we continue to pursue our seniors housing investment strategy.

Consolidated Results of Operations

Three Months Ended June 30, 2026 Compared to Three Months Ended June 30, 2025

Three Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

$ Change

  ​ ​ ​

(in thousands)

Revenue

 

  ​

 

 

  ​

 

Rental revenue

$

37,060

$

37,880

$

(820)

Resident fees and services

1,841

1,841

Other income

 

846

 

89

 

757

Total revenue

 

39,747

 

37,969

1,778

Expenses

General and administrative

 

5,221

 

6,025

 

(804)

Operating expenses

 

10,034

 

8,216

 

1,818

Depreciation expense

 

11,443

 

11,307

 

136

Amortization expense

 

3,833

 

3,984

 

(151)

Interest expense

8,806

8,009

797

Total expenses

 

39,337

 

37,541

 

1,796

Income before other income (expense)

410

428

(18)

Gain on sale of investment properties

71,881

207

71,674

Equity loss from unconsolidated joint ventures

(10)

(50)

40

Net income

$

72,281

$

585

$

71,696

Revenue

Total Revenue

Total revenue for the three months ended June 30, 2026 was $39.7 million, compared to $38.0 million for the same period in 2025, representing an increase of $1.7 million. The increase was primarily driven by $1.8 million of resident fees and services recognized during the one-month period that we owned the Landing and the Riviera. These increases were partially offset by the impact of dispositions completed during 2026 and 2025. Within total revenue, $5.6 million was recognized from net lease expense recoveries during the three months ended June 30, 2026, compared to $5.4 million for the same period in 2025.

Expenses

General and Administrative

General and administrative expenses for the three months ended June 30, 2026 were $5.2 million, compared to $6.0 million for the same period in 2025, a decrease of $0.8 million. The decrease was primarily driven by a decrease in professional fees of $0.4 million, non-cash LTIP compensation expense of $0.3 million, and general corporate expenses of $0.1 million.

Operating Expenses

Operating expenses for the three months ended June 30, 2026 were $10.0 million, compared to $8.2 million for the same period in 2025, an increase of $1.8 million. The increase was primarily attributable to $1.6 million of operating expenses related to the Landing

-38-

Table of Contents

and the Riviera for the one-month period that we owned these properties during the three months ended June 30, 2026. Operating expenses in the existing portfolio also increased by $0.4 million, reflecting higher property‑level costs year-over-year. These increases were partially offset by the dispositions completed during 2026 and 2025. Included in these amounts were $5.6 million of recoverable property operating expenses incurred during the three months ended June 30, 2026, compared to $5.4 million for the same period in 2025.

Depreciation Expense

Depreciation expense for the three months ended June 30, 2026 was $11.4 million, compared to $11.3 million for the same period in 2025, an increase of $0.1 million. The increase was primarily driven by our 2026 acquisitions, partially offset by the impact of dispositions completed during 2026 and 2025.

Amortization Expense

Amortization expense for the three months ended June 30, 2026 was $3.8 million, compared to $4.0 million for the same period in 2025, a decrease of $0.2 million. The decrease was primarily driven by decreases on the existing portfolio during that same period.

Interest Expense

Interest expense for the three months ended June 30, 2026 was $8.8 million, compared to $8.0 million for the same period in 2025, an increase of $0.8 million. The increase was partially driven by higher interest rates resulting from the expiration in April 2026 of the prior interest rate swaps on our Term Loan A and the replacement of those swaps with new interest rate swaps on the Term Loan A tranches that fix the SOFR component of the applicable interest rate at higher rates than the prior swaps. The increase was also partially attributable to higher average borrowings during the three months ended June 30, 2026 compared to the same period in 2025.

The weighted average interest rate of our debt for the three months ended June 30, 2026 was 4.32% compared to 4.03% for the same period in 2025. Additionally, the weighted average interest rate and term of our debt was 4.56% and 3.6 years, respectively, at June 30, 2026, compared to 4.09% and 1.6 years, respectively, at June 30, 2025.

Income Before Other Income (Expense)

Income before other income (expense) for the three months ended June 30, 2026 was $0.4 million, compared to $0.4 million for the same period in 2025.

Gain on Sale of Investment Properties

During the three months ended June 30, 2026, we recognized a gain on sale of investment properties of $71.9 million related to properties sold in connection with the establishment of the IRF Joint Venture. During the three months ended June 30, 2025, we completed one disposition recognizing a gain on sale of investment properties of $0.2 million.

Equity Loss from Unconsolidated Joint Ventures

Equity Loss from Unconsolidated Joint Ventures for the three months ended June 30, 2026 was $10 thousand, compared to $50 thousand for the same period in 2025, a decrease of $40 thousand.

Net Income

Net income for the three months ended June 30, 2026 was $72.3 million, compared to net income of $0.6 million for the same period in 2025, an increase of $71.7 million.

-39-

Table of Contents

Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025

Six Months Ended June 30, 

2026

2025

$ Change

(in thousands)

Revenue

 

  ​

 

  ​

  ​

Rental revenue

$

75,081

$

72,475

$

2,606

Resident fees and services

1,841

1,841

Other income

 

889

 

112

 

777

Total revenue

 

77,811

 

72,587

 

5,224

Expenses

 

  ​

 

 

  ​

General and administrative

 

10,310

 

9,645

 

665

Operating expenses

 

19,284

 

15,800

 

3,484

Depreciation expense

 

22,530

 

21,614

 

916

Amortization expense

 

7,573

 

7,504

 

69

Interest expense

 

16,039

 

15,176

 

863

Total expenses

 

75,736

 

69,739

 

5,997

Income before other income (expense)

2,075

2,848

(773)

Gain on sale of investment properties

71,881

1,565

70,316

Equity loss from unconsolidated joint venture

(21)

(91)

70

Net income

$

73,935

$

4,322

$

69,613

Revenue

Total Revenue

Total revenue for the six months ended June 30, 2026 was $77.8 million, compared to $72.6 million for the same period in 2025, representing an increase of $5.2 million. The increase was primarily attributable to $2.5 million of rental revenue from acquisitions completed during the six months ended June 30, 2025, reflecting a full six months of ownership in 2026. The increase was also driven by $2.4 million of growth in our existing portfolio and $1.8 million of resident fees and services recognized during the one-month period in which we owned the Landing and the Riviera. These increases were partially offset by the impact of dispositions completed during 2026 and 2025. Within total revenue, $11.9 million was recognized from net lease expense recoveries during the six months ended June 30, 2026, compared to $10.6 million for the same period in 2025.

Expenses

General and Administrative

General and administrative expenses for the six months ended June 30, 2026 were $10.3 million, compared to $9.6 million for the same period in 2025, an increase of $0.7 million. The increase was primarily driven by an increase in non-cash LTIP compensation expense of $0.7 million.

Operating Expenses

Operating expenses for the six months ended June 30, 2026 were $19.3 million, compared to $15.8 million for the same period in 2025, an increase of $3.5 million. The increase was primarily attributable to $1.6 million of SHOP operating expenses recognized during the one-month period in which we owned the Landing and the Riviera, $1.3 million of operating expenses from acquisitions completed during the six months ended June 30, 2025, reflecting a full six months of ownership in 2026, and $1.1 million of growth in our existing portfolio, reflecting higher property‑level costs year-over-year. These increases were partially offset by the impact of dispositions completed during 2026 and 2025. Included in these amounts were $11.9 million of recoverable property operating expenses incurred during the six months ended June 30, 2026, compared to $10.6 million for the same period in 2025.

-40-

Table of Contents

Depreciation Expense

Depreciation expense for the six months ended June 30, 2026 was $22.5 million, compared to $21.6 million for the same period in 2025, an increase of $0.9 million. The increase was primarily attributable to $1.2 million of depreciation expense from acquisitions completed during the six months ended June 30, 2025, reflecting a full six months of ownership in 2026, and $0.4 million of SHOP depreciation expense recognized during the one-month period in which we owned the Landing and the Riviera. These increases were partially offset by the impact of dispositions completed during 2026 and 2025.

Amortization Expense

Amortization expense for the six months ended June 30, 2026 was $7.6 million, compared to $7.5 million for the same period in 2025, an increase of $0.1 million. The increase was primarily attributable to $0.7 million of amortization expense from acquisitions completed during the six months ended June 30, 2025, reflecting a full six months of ownership in 2026, and $0.1 million of SHOP amortization expense recognized during the one month period in which we owned the Landing and the Riviera. These increases were partially offset by $0.5 million of amortization expense decreases in our existing portfolio, and $0.2 million due to the impact of dispositions completed during 2026 and 2025.

Interest Expense

Interest expense for the six months ended June 30, 2026 was $16.0 million, compared to $15.2 million for the same period in 2025, an increase of $0.8 million. The increase was partially driven by higher interest rates resulting from the expiration in April 2026 of the prior interest rate swaps on our Term Loan A and the replacement of those swaps with new interest rate swaps on the Term Loan A tranches that fixed the SOFR component of the applicable interest rate at higher rates than the prior swaps. The increase was also partially attributable to higher average borrowings during the six months ended June 30, 2026 compared to the same period in 2025.

The weighted average interest rate of our debt for the six months ended June 30, 2026 was 4.03% compared to 3.93% for the same period in 2025. Additionally, the weighted average interest rate and term of our debt was 4.56% and 3.6 years, respectively, at June 30, 2026 compared to 4.09% and 1.6 years, respectively, at June 30, 2025.

Income Before Other Income (Expense)

Income before other income (expense) for the six months ended June 30, 2026 was $2.1 million, compared to $2.8 million for the same period in 2025, a decrease of $0.7 million.

Gain on Sale of Investment Properties

During the six months ended June 30, 2026, we recognized a gain on sale of investment properties of $71.9 million related to properties sold in connection with the establishment of the IRF Joint Venture. During the six months ended June 30, 2025, we completed three dispositions and recognized a gain on the sale of investment properties of $1.6 million.

Equity Loss from Unconsolidated Joint Ventures

Equity Loss from Unconsolidated Joint Ventures for the six months ended June 30, 2026 was $21 thousand, compared to $91 thousand for the same period in 2025, a decrease of $70 thousand.

Net Income

Net income for the six months ended June 30, 2026 was $73.9 million, compared to net income of $4.3 million for the same period in 2025, an increase of $69.6 million.

Assets and Liabilities

As of June 30, 2026 and December 31, 2025 our principal assets consisted of investments in real estate, net, of $1.2 billion and $1.2 billion, respectively. We completed two acquisitions and seven dispositions during the six months ended June 30, 2026. Our liquid assets consisted primarily of cash and cash equivalents and restricted cash of $12.9 million and $11.9 million, as of June 30, 2026 and December 31, 2025, respectively.

-41-

Table of Contents

The increase in our cash and cash equivalents and restricted cash balances to $12.9 million as of June 30, 2026, compared to $11.9 million as of December 31, 2025, was primarily due to net proceeds received from the sale of investment properties, and net cash provided by operating activities, partially offset by net repayments on our Credit Facility, funds used to acquire investment properties and joint ventures, the payment of dividends to common and preferred stockholders as well as holders of OP Units and LTIP Units, and funds used for capital expenditures on existing real estate investments and leasing commissions.

The decrease in our total liabilities to $687.7 million as of June 30, 2026 compared to $712.4 million as of December 31, 2025, was primarily the result of higher net repayments on our Credit Facility and lower dividends payable.

Cash Flow Information

Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

$ Change

(in thousands)

Cash provided by operating activities

$

35,909

$

34,411

$

1,498

Cash used in investing activities

(81,714)

(66,449)

(15,265)

Cash provided by financing activities

46,836

32,322

14,514

Increase in cash and cash equivalents and restricted cash

$

1,031

$

284

$

747

Net cash provided by operating activities for the six months ended June 30, 2026 was $35.9 million, compared to $34.4 million for the same period in 2025. Net cash provided by operating activities increased primarily due to the impact of our 2026 and 2025 acquisitions.

Net cash used in investing activities for the six months ended June 30, 2026 was $81.7 million, compared to $66.4 million for the same period in 2025. Net cash used in investing activities increased primarily due to higher net acquisition activity in 2026 compared to 2025.

Net cash provided by financing activities for the six months ended June 30, 2026 was $46.8 million, compared to $32.3 million for the same period in 2025. Net cash provided by financing activities increased primarily due to higher net proceeds received from preferred stock offerings. These increases were partially offset by net repayments on our Credit Facility, and lower dividends paid to common and preferred stockholders as well as holders of OP Units and LTIP Units.

Non-GAAP Financial Measures

Management considers certain non-GAAP financial measures to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of those measures to the most directly comparable GAAP financial measure.

The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Report.

Funds from Operations, Core Funds from Operations, and Funds Available for Distribution

Funds from operations attributable to common stockholders and noncontrolling interest (“FFO”), and core FFO attributable to common stockholders and noncontrolling interest (“Core FFO”) and funds available for distribution attributable to common stockholders

-42-

Table of Contents

and noncontrolling interest (“FAD”) are non-GAAP financial measures within the meaning of the rules of the SEC. The Company considers FFO, Core FFO, and FAD to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results.

In accordance with the National Association of Real Estate Investment Trusts’ (“NAREIT”) definition, FFO means net income or loss computed in accordance with GAAP before noncontrolling interests of holders of OP Units and LTIP Units, excluding gains (or losses) from sales of property and extraordinary items, property impairment losses, less preferred stock dividends, plus real estate-related depreciation and amortization (excluding amortization of debt issuance costs and the amortization of above and below market leases), and after adjustments for unconsolidated partnerships and joint ventures calculated to reflect FFO on the same basis. Because FFO excludes real estate-related depreciation and amortization (other than amortization of debt issuance costs and above and below market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

Core FFO is a non-GAAP measure used by many investors and analysts to measure a real estate company’s operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates Core FFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company these items include recurring acquisition and disposition costs, loss on the extinguishment of debt, recurring straight line deferred rental revenue, recurring stock-based compensation expense, recurring amortization of above and below market leases, recurring amortization of debt issuance costs, severance and transition related expense, costs related to our reverse stock split, and other items related to unconsolidated partnerships and joint ventures.

We calculate FAD by subtracting from Core FFO capital expenditures, including tenant improvements, leasing commissions and building capital. Management believes FAD is useful in analyzing the portion of cash flow that is available for distribution to stockholders and unitholders. Investors, analysts and the Company utilize FAD as an indicator of common dividend potential.

Management believes that reporting Core FFO in addition to FFO and FAD is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis.

-43-

Table of Contents

A reconciliation of net income to FFO and Core FFO and FAD for the three and six months ended June 30, 2026 and 2025 is as follows. All per share, per share and unit, and weighted average share and unit amounts have been adjusted to reflect the impact of the Reverse Stock Split.

Three Months Ended June 30, 

  ​ ​ ​

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

(unaudited, in thousands except per share and unit amounts)

Net income

$

72,281

$

585

$

73,935

$

4,322

Less: Preferred stock dividends

 

(2,982)

 

(1,455)

 

(5,455)

 

(2,911)

Depreciation and amortization expense

15,251

15,266

30,053

29,072

Depreciation and amortization expense from unconsolidated joint ventures

73

73

146

122

Gain on sale of investment properties

(71,881)

(207)

(71,881)

(1,565)

FFO attributable to common stockholders and noncontrolling interest

$

12,742

$

14,262

$

26,798

$

29,040

Amortization of above (below) market leases, net

 

150

(60)

296

392

Straight line deferred rental revenue

 

122

(479)

(82)

(536)

Stock-based compensation expense

 

1,378

1,728

2,607

1,879

Amortization of debt issuance costs

 

707

559

1,514

1,118

Severance and transition related expense

567

671

Other adjustments from unconsolidated joint ventures

2

20

(17)

51

Core FFO attributable to common stockholders and noncontrolling interest

$

15,101

$

16,597

$

31,116

$

32,615

Net income (loss) attributable to common stockholders per share – basic and diluted

$

4.78

$

(0.06)

$

4.73

$

0.10

FFO attributable to common stockholders and noncontrolling interest per share and unit

$

0.88

$

0.98

$

1.85

$

2.00

Core FFO attributable to common stockholders and noncontrolling interest per share and unit

$

1.04

$

1.14

$

2.15

$

2.25

Weighted Average Shares and Units Outstanding – basic and diluted

 

14,485

14,530

14,450

14,501

Weighted Average Shares and Units Outstanding:

Weighted Average Common Shares

 

13,235

13,376

13,235

13,375

Weighted Average OP Units

 

444

449

444

449

Weighted Average LTIP Units

 

806

705

771

677

Weighted Average Shares and Units Outstanding – basic and diluted

 

14,485

 

14,530

 

14,450

 

14,501

Core FFO attributable to common stockholders and noncontrolling interest

$

15,101

$

16,597

$

31,116

$

32,615

Tenant improvements

(762)

(878)

(1,356)

(1,582)

Leasing commissions

(367)

(558)

(917)

(673)

Building capital

(2,269)

(1,087)

(3,819)

(2,994)

FAD attributable to common stockholders and noncontrolling interest

$

11,703

$

14,074

$

25,024

$

27,366

Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (EBITDAre) and Adjusted EBITDAre

The Company calculates EBITDAre in accordance with standards established by NAREIT and defines EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, gain or loss on the sale of investment properties, property impairment losses, and adjustments for unconsolidated partnerships and joint ventures to reflect EBITDAre on the same basis, as applicable. The Company defines Adjusted EBITDAre as EBITDAre plus loss on extinguishment of debt, non-cash stock compensation expense, non-cash intangible amortization related to above and below market leases, severance and

-44-

Table of Contents

transition related expense, expenses related to our reverse stock split, transaction expense, adjustments related to our investments in unconsolidated joint ventures, and other normalizing items. Management considers EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

A reconciliation of net income to EBITDAre and Adjusted EBITDAre for the three and six months ended June 30, 2026 and 2025 is as follows:

Three Months Ended June 30, 

Six Months Ended June 30, 

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

(unaudited and in thousands)

Net income

$

72,281

$

585

$

73,935

$

4,322

Interest expense

 

8,806

8,009

16,039

15,176

Depreciation and amortization expense

15,276

15,291

30,103

29,118

Unconsolidated joint venture EBITDAre adjustments (1)

112

114

223

199

Gain on sale of investment properties

(71,881)

(207)

(71,881)

(1,565)

EBITDAre

$

24,594

$

23,792

$

48,419

$

47,250

Stock-based compensation expense

1,378

1,728

2,607

1,879

Amortization of above (below) market leases, net

 

150

 

(60)

296

392

Severance and transition related expense

567

671

Interest rate swap mark-to-market at unconsolidated joint ventures

2

19

(17)

55

Adjusted EBITDAre

$

26,124

$

26,046

$

51,305

$

50,247

(1)Includes joint venture interest, depreciation and amortization, and gain on sale of investment properties, if applicable, included in unconsolidated joint ventures net income or loss.

Net Operating Income (NOI), Cash NOI, and Same-Property Cash NOI

The Company considers net operating income (“NOI”) to be an appropriate supplemental measure to net income because it helps both investors and management understand the core operations of our properties. We define NOI as total net (loss) income, plus depreciation and amortization expenses, general and administrative expenses, transaction expenses, impairments, (gain) loss on sale of investment properties, interest expense, and other non-operating items. Cash NOI and Same-Property Cash NOI are key performance indicators. Management considers these to be supplemental measures that allow investors, analysts and Company management to measure unlevered property-level cash operating results. The Company defines Cash NOI as NOI excluding non-cash items such as above and below market lease intangibles and straight-line rent. Cash NOI is historical and not necessarily indicative of future results. Same-Property Cash NOI compares Cash NOI for stabilized properties. Stabilized properties are properties that have been included in operations for the duration of the year-over-year comparison period presented. Accordingly, stabilized properties exclude properties that were recently acquired or disposed of, properties classified as held for sale, properties undergoing redevelopment, and newly

-45-

Table of Contents

redeveloped or developed properties. Same-Property Cash NOI also excludes lease terminations fees and joint ventures and other income in order to remove non-recurring items and joint venture-related income from our NOI.

Three Months Ended June 30, 

Six Months Ended June 30, 

2026

  ​ ​ ​

2025

2026

  ​ ​ ​

2025

(unaudited and in thousands)

Net income

$

72,281

$

585

$

73,935

$

4,322

General and administrative

 

5,221

 

6,025

 

10,310

 

9,645

Depreciation and amortization expense

15,276

15,291

30,103

29,118

Interest expense

8,806

8,009

16,039

15,176

Gain on sale of investment properties

(71,881)

(207)

(71,881)

(1,565)

Proportionate share of unconsolidated joint venture adjustments

114

133

206

253

NOI

$

29,817

$

29,836

$

58,712

$

56,949

Amortization of above (below) market leases, net

150

(60)

296

392

Straight line deferred rental revenue

 

122

 

(479)

 

(82)

 

(536)

Proportionate share of unconsolidated joint venture adjustments

(2)

(3)

(4)

(8)

Cash NOI

$

30,087

$

29,294

$

58,922

$

56,797

Assets not held for all periods

(5,025)

(5,214)

Lease termination fees

(12)

Joint ventures and other income

(948)

(157)

Same-Property Cash NOI

$

24,114

$

23,911

Liquidity and Capital Resources

General

Our short-term (up to 12 months) liquidity requirements include:

Interest expense and scheduled principal payments on outstanding indebtedness;
General and administrative expenses;
Property operating expenses;
Property acquisitions;
Distributions on our common and preferred stock and OP Units and LTIP Units;
Increased capital requirements for our joint ventures;
Repurchases of our common stock; and
Capital and tenant improvements and leasing costs.

On May 5, 2026, the Board of Directors reduced the Company’s monthly common stock dividend from $0.25 per share to $0.16 per share. The Company is resizing its dividend to focus on retaining cash flow and to accelerate the Company’s acquisition strategy and accelerate the ramp of its SHOP portfolio.

In 2026, we are contractually obligated to pay, or have capital commitments for, principal and interest payments on our outstanding debt and ground and operating lease expenses. In addition, if we decide to redeem our Series A Preferred Stock in full, we would have to pay the liquidation preference of $77.6 million plus accrued dividends, fees and expenses.

Our long-term (beyond 12 months) liquidity requirements consist primarily of funds necessary to pay for acquisitions, capital and tenant improvements at our properties, scheduled debt maturities, general and administrative expenses, operating expenses, common

-46-

Table of Contents

stock repurchases, and distributions. Beyond 2026, we are contractually obligated to pay, or have capital commitments for, principal and interest payments on our outstanding debt and ground and operating lease expenses.

We expect to satisfy our short and long-term liquidity needs through various internal and external sources, including cash flow from operations, debt financing, sales of additional equity securities, the issuance of OP Units in connection with acquisitions of additional properties, proceeds from select property dispositions and recapitalization transactions.

Sources of Liquidity

Our primary internal sources of liquidity include cash flow from operations and proceeds from select property dispositions and recapitalization transactions. Our primary external sources of liquidity include net proceeds received from equity issuances, including the issuance of OP Units in connection with acquisitions of additional properties, and debt financing, including borrowings under our Credit Facility, secured term loans and Senior Note Facility.

ATM Program

In January 2024, the Company and the Operating Partnership implemented a $300 million “at-the-market” equity offering program, pursuant to which we may offer and sell (including through forward sales), from time to time, shares of our common stock (the “2024 ATM Program”). No shares were sold under the 2024 ATM Program during the six months ended June 30, 2026 or from July 1, 2026 through August 3, 2026. As of June 30, 2026, the Company has $288.0 million remaining available under the 2024 ATM Program.

In February 2026, the Company and the Operating Partnership implemented a $75 million “at-the-market” equity offering program, pursuant to which the Company may offer and sell (including through forward sales), from time-to-time, shares of its 8.00% Series B Cumulative Redeemable Preferred Stock (the “2026 Series B Preferred ATM Program”). No shares were sold under the 2026 Series B Preferred ATM Program during the six months ended June 30, 2026 or from July 1, 2026 through August 3, 2026.

Debt Financing

Credit Facility. Our Credit Facility consists of (i) the $350 million Term Loan A Tranches, (ii) the $150 million Term Loan B, and (iii) the $400 million Revolver. The Credit Facility also contains a $500 million accordion feature. As of August 3, 2026, we had unutilized borrowing capacity under the Credit Facility of $245.5 million.

The Credit Facility is an unsecured facility with a maturity of (i) October 2029 for the Revolver (subject to two, six-month extension options), (ii) October 2029, October 2030, and April 2031 for the Term Loan A Tranches, and (iii) February 2028 for Term Loan B. Interest rates on amounts outstanding under the Credit Facility equal SOFR plus a borrowing spread based on the current pricing grid in the Credit Facility.

As of June 30, 2026, we had 11 interest rate swaps that are used to manage our interest rate risk. Four of our interest rate swaps relate to our Term Loan B with a combined notional value of $150 million that fix the SOFR component on Term Loan B through January 2028 at 2.54%. Seven of our interest rate swaps relate to our Term Loan A tranches that fix the SOFR component of the Term Loan A Tranches with a combined notional value of $350 million at rates between 3.24% to 3.32% and have maturities in October 2029, October 2030, and April 2031. The seven interest rate swaps related to our Term Loan A tranches became effective in May 2026 following the maturity of five previous interest rate swaps that fixed the SOFR component through April 2026 at 1.36%.

We are subject to a number of financial covenants under the Credit Facility, including, among other things, the following as of the end of each fiscal quarter, (i) a maximum consolidated unsecured leverage ratio of less than 60%, (ii) a maximum consolidated secured leverage ratio of less than 30%, (iii) a maximum consolidated secured recourse leverage ratio of less than 10%, (iv) a minimum fixed charge coverage ratio of 1.50:1.00, (v) a minimum unsecured interest coverage ratio of 1.50:1.00, (vi) a maximum consolidated leverage ratio of less than 60%, (vii) a maximum cash investment in joint ventures of 10% of total asset value and (viii) a minimum net worth of $595.6 million plus 75% of all net proceeds raised through equity offerings subsequent to June 30, 2025. As of June 30, 2026, management believed it complied with all of the financial and non-financial covenants contained in the Credit Facility.

-47-

Table of Contents

Total Fixed Debt. Our fixed debt totaled $501.1 million on a gross basis at June 30, 2026, with a weighted average interest rate of 4.42% based on our interest rate swaps and current leverage. The weighted average maturity of our fixed debt was 3.4 years at June 30, 2026.

Other Fixed Debt. We have $1.1 million in gross notes payable as of June 30, 2026. This debt is comprised of one instrument.

Senior Note Facility

On March 2, 2026, the Company entered into a Master Note and Guaranty Agreement (the “Senior Note Agreement”) with NYL Investors LLC and certain of its affiliates (collectively, the “Purchasers”). The Agreement establishes an uncommitted senior unsecured note facility pursuant to which the Company may issue senior unsecured promissory notes (“Notes”) from time to time in one or more series to the Purchasers in an aggregate principal amount of up to $150.0 million. The Senior Note Agreement does not obligate the Purchasers to purchase any Notes, and each issuance is subject to the Purchasers’ discretion and satisfaction of customary conditions. Notes may be issued under the Senior Note Agreement during a period ending on the earliest of (i) the third anniversary of the effective date of the Senior Note Agreement, (ii) termination of the facility by either party upon written notice, (iii) termination following certain events of default, or (iv) acceleration of the Notes and termination of the facility. Notes issued under the Agreement may have maturities of up to ten years and will bear interest at rates determined at the time of issuance based on spreads over U.S. Treasury securities. As of June 30, 2026, no Notes had been issued or were outstanding under the Senior Note Agreement.

Debt Activity

During the six months ended June 30, 2026, we borrowed $241.1 million under the Credit Facility and repaid $263.3 million, for a net amount repaid of $22.2 million. During the six months ended June 30, 2025, we borrowed $94.5 million under the Credit Facility and repaid $28.5 million, for a net amount borrowed of $66.0 million. As of June 30, 2026, the net outstanding Credit Facility balance was $641.0 million and as of August 3, 2026, we had unutilized borrowing capacity under the revolver component of the Credit Facility (the “Revolver”) of $245.5 million.

Series C Convertible Preferred Stock Offering

On May 29, 2026 and June 2, 2026, the Company issued and aggregate of 1,000,000 shares of its Series C Convertible Preferred Stock, for aggregate gross proceeds of $100.0 million. The Series C Convertible Preferred Stock provides for cumulative dividends at a rate of 6.00% per annum, which increases to 8.00% on June 2, 2030 (the date that is four years after the date of last issuance) to the extent the Series C Convertible Preferred Stock has not been redeemed or converted as of that date and increases by an additional 2.00% on each subsequent anniversary thereafter, up to a maximum of 12.00%, to the extent the Series C Convertible Preferred Stock has not been redeemed or converted as of such anniversary dates. The Series C Convertible Preferred Stock is convertible into shares of the Company’s common stock at an initial conversion rate of 2.32558 shares of common stock per share of Series C Convertible Preferred Stock, which is based on an implied conversion price of $43.00 per share of common stock, subject to customary anti-dilution adjustments. The Company may redeem the Series C Convertible Preferred Stock, in whole or in part, at its option on or after June 2, 2030 (the date that is four years after the date of last issuance), at a cash redemption price equal to the liquidation preference of $100 per share, plus accumulated and unpaid regular dividends, including any defaulted regular dividends. The Series C Convertible Preferred Stock generally has no voting rights, except for limited voting rights with respect to certain matters affecting its rights and preferences. In addition, upon issuance of the Series C Convertible Preferred Stock, the Company’s ability to make distributions with respect to, or redeem, purchase or acquire, or make liquidation payments on, any other shares of capital stock ranking junior to or on a parity with the Series C Convertible Preferred Stock became subject to certain restrictions in the event that the Company does not declare distributions on the Series C Convertible Preferred Stock during any distribution period.

-48-

Table of Contents

Common Stock Repurchase Program

In August 2025, the Board approved a $50 million common stock repurchase program (the “Stock Repurchase Program”). Under the Stock Repurchase Program, we may purchase up to $50 million of our outstanding shares of common stock from time to time in the open market, including through block purchases, through privately negotiated transactions or pursuant to any Rule 10b5-1 trading plan, in accordance with applicable securities laws. The specific timing, price and size of purchases will depend on prevailing stock prices, general economic and market conditions and other considerations. The Stock Repurchase Program does not obligate us to repurchase any dollar amount or number of shares of our common stock and may be suspended or discontinued at any time. No shares were repurchased during the six months ended June 30, 2026 or from July 1, 2026 through August 3, 2026.

Off-Balance Sheet Arrangements

As of June 30, 2026, we have investments in four unconsolidated joint ventures with ownership interests of 49%, 49%, 15% and 12.5%. The aggregate carrying amount of debt, including both our and our partners’ share, incurred by these ventures was approximately $141.5 million (of which our proportionate share is approximately $24.1 million). See Note 2 (Summary of Significant Accounting Policies) to our accompanying condensed consolidated financial statements for additional information. We have no other off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Market risk includes risks that arise from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices and other market changes that affect market sensitive instruments. In pursuing our business and investment objectives, we expect that the primary market risk to which we will be exposed is interest rate risk.

We may be exposed to the effects of interest rate changes primarily as a result of debt used to acquire healthcare facilities, including borrowings under the Credit Facility. The analysis below presents the sensitivity of the value of our variable rate financial obligations to selected changes in market interest rates. The range of changes chosen reflects our view of changes which are reasonably possible over a one-year period.

As of June 30, 2026, we had $141.0 million of unhedged borrowings outstanding under the Revolver (before the netting of unamortized debt issuance costs) that bears interest at a variable rate. See “Management’s Discussion and Analysis of Financial Condition and Results of Operation—Liquidity and Capital Resources,” for a detailed discussion of our Credit Facility. On June 30, 2026, SOFR on our outstanding floating-rate borrowings was 3.65%. Assuming no increase in the amount of our variable interest rate debt, if SOFR increased 100 basis points, our cash flow would decrease by approximately $1.4 million annually. Assuming no increase in the amount of our variable rate debt, if SOFR were reduced 100 basis points, our cash flow would increase by approximately $1.4 million annually.

Our interest rate risk management objectives are to limit the impact of interest rate changes on earnings and cash flows and to lower overall borrowing costs. To achieve our objectives, we may borrow at fixed rates or floating rates. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Sources of Liquidity—Debt Financing,” for a description of our interest rate swaps.

We may enter into additional derivative financial instruments, including interest rate swaps and caps, in order to mitigate our interest rate risk on our future borrowings. We will not enter into derivative transactions for speculative purposes.

In addition to changes in interest rates, the value of our investments is subject to fluctuations based on changes in local and regional economic conditions and changes in the creditworthiness of tenants/operators and borrowers, which may affect our ability to refinance our debt if necessary.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

The Company’s management, including its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on such evaluation, the Company’s

-49-

Table of Contents

Chief Executive Officer and Chief Financial Officer concluded that as of June 30, 2026, the Company’s disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information it is required to disclose in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

No changes were made to our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures and the Company’s internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and the Company’s internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

PART II OTHER INFORMATION

Item 1. Legal Proceedings

We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on our financial condition or results of operations. From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. There can be no assurance that these matters that arise in the future, individually or in the aggregate, will not have a material adverse effect on our financial condition or results of operations in any future period.

Item 1A. Risk Factors

Information on risk factors can be found in Part I, Item 1A (Risk Factors) of our 2025 Annual Report. Except as set forth below, there have been no material changes from the risk factors previously disclosed in our 2025 Annual Report. Some statements in this Quarterly Report on Form 10-Q constitute forward-looking statements. Please refer to Part I, Item 2 of this Quarterly Report on Form 10-Q entitled “Special Note Regarding Forward-Looking Statements.”

Our SHOP segment may expose us to various operational risks, liabilities and claims that could adversely affect our ability to generate revenues or increase our costs and could adversely affect our business, financial condition and results of operations.

Under the REIT tax rules, the senior housing communities in our SHOP segment that are “qualified healthcare properties” generally must be operated and managed for us by third-party managers and we have limited rights to direct or influence the business or operations of those communities. Both our qualified and non-qualified healthcare properties in our SHOP segment are managed or sub-managed by third-party managers. However, in each case, we nonetheless participate directly in the financial performance of the communities’ operations and are ultimately responsible for all operational risks and other liabilities of such properties, other than those arising out of certain actions by our managers, such as gross negligence, fraud or willful misconduct. These risks include, and our financial performance is impacted by, among other things, fluctuations in occupancy levels, the inability to charge desirable resident fees (including anticipated increases in those fees), increases in the cost of food, supplies, energy, labor (as a result of labor shortages, unionization, inflation or otherwise) or other services, rent control regulations, national and regional economic conditions, the imposition of new or increased taxes, capital expenditure requirements, changes in management or equity, accounting misstatements, professional and general liability claims, litigation and regulatory actions and the availability and cost of insurance. Additionally, new or smaller third-party managers may have less experience in managing these senior housing communities and may require more oversight or attention. Any one or a combination of these factors could impact the performance of our SHOP segment, which could adversely affect our business, financial condition and results of operations.

-50-

Table of Contents

We generally hold the applicable healthcare license and enroll in applicable government healthcare programs on behalf of the properties in our SHOP segment, which subjects us to potential liability under various healthcare laws and regulations.

Our inability to renew our management agreements with our SHOP managers and sub-managers on as favorable terms or at all, and our inability when necessary, to effectively and efficiently transition a SHOP community to a new manager or sub-manager, may have an adverse effect on our business, financial condition and results of operations.

We are party to management agreements with our SHOP managers and sub-managers. While our management and sub-management agreements may be renewed, either pursuant to pre-negotiated renewal rights or through negotiation, there can be no assurance that our managers or sub-managers will renew with us. Even if a manager or sub-manager renews its agreement with us, we cannot assure you that the renewals will be on favorable terms. This risk may be exacerbated if market conditions at the time of the renewal are not as favorable as they were at the time the agreement was initially entered into or if the manager or sub-manager is subject to financial or operational difficulties.

Our management and sub-management agreements provide us and our managers and sub-managers with termination rights in certain circumstances. If our management or sub-management agreements are not renewed or are otherwise terminated, we may attempt to transition those properties to one or more managers or sub-managers or reposition those properties for an alternative use. We may not be successful in identifying suitable replacements or entering into management or sub-management agreements or other arrangements with new managers or sub-managers on a timely basis or on terms as favorable to us as our current management or sub-management agreements, if at all.

During transition periods to new managers or sub-managers or in connection with repositioning the property, the attention of existing managers or sub-managers may be diverted from the performance of the properties, which could cause the financial and operational performance at those properties to decline and could increase exposure to operational and compliance risks. We may be required to fund certain expenses and obligations (such as real estate taxes, debt costs and maintenance expenses) or provide certain indemnities to preserve the value of, and avoid the imposition of liens on, our properties while they are being repositioned. Our ability to transition our properties to a suitable replacement manager or sub-manager or reposition our properties could be significantly delayed or limited by state licensing, receivership, certificates of need, Medicaid change-of-ownership rules or other legal and regulatory requirements or restrictions. The inability to replace a manager or sub-manager on a timely or successful basis could have an adverse effect on our business, financial condition and results of operations.

Significant legal or regulatory proceedings could subject us or our managers or sub-managers to increased operating costs and substantial uninsured liabilities, which could adversely affect our or their liquidity, financial condition and results of operations.

From time to time, we or our managers or sub-managers may be subject to lawsuits, investigations, claims and other legal or regulatory proceedings arising out of our or their alleged actions or inactions. Also, in certain circumstances, regardless of whether we are a named party in a lawsuit, investigation, claim or other legal or regulatory proceeding, we may be contractually obligated to indemnify, defend and hold harmless our managers, sub-managers and other third parties against, or may otherwise be responsible for such actions, proceedings or claims. These claims may include, among other things, professional liability and general liability claims, commercial liability claims, unfair business practices claims, class action claims, employment-related claims, as well as regulatory proceedings, including proceedings related to our SHOP segment, where we are typically the holder of the applicable healthcare license. In addition, some of our properties may be in states in which the litigation environment may pose a significant business risk to us.

In our operating assets, we will be generally responsible for all liabilities of the properties, including any lawsuits, investigations, claims and other legal or regulatory proceedings, other than those arising out of certain limited actions by our managers or sub-managers, such as those caused by gross negligence, fraud or willful misconduct. As a result, we have exposure to, among other things, professional and general liability claims, employment-related claims and the associated litigation and other costs related to defending and resolving such claims, some of which may be uninsured, either as a result of insufficient coverage or unavailability of coverage at a reasonable price.

If one of our managers or sub-managers fails to comply with applicable law or regulation, we may be held responsible, which could subject us to civil, criminal and administrative penalties, including the loss or suspension of accreditation, licenses or certificates of need with respect to a single community or more broadly; suspension of or nonpayment for new admissions; denial of reimbursement; fines; suspension, decertification, or exclusion from federal, state or foreign healthcare programs; or facility closure. In addition, we cannot assure you that any contractual obligations to indemnify, defend and hold us harmless from such liabilities will be satisfied by third parties, or that any amounts held in escrow for such purpose will be sufficient.

-51-

Table of Contents

An unfavorable resolution of any such lawsuit, investigation, claim or other legal or regulatory proceeding could materially and adversely affect our or our managers’ or sub-managers’ liquidity, financial condition and results of operations, and may not be protected by sufficient or any insurance coverage. Even with a favorable resolution of litigation or a proceeding, the effect of litigation and other potential litigation and proceedings may divert the attention of management and materially increase operating costs we or our managers or sub-managers incur. Negative publicity with respect to any lawsuits, claims or other legal or regulatory proceedings may also negatively impact their or our or the affected properties’ reputation.

Our business may be subject to lawsuits or other legal or regulatory proceedings such as professional or general liability litigation alleging wrongful death and negligence claims, some of which may result in large damage awards and not be indemnified or subject to sufficient insurance coverage, may require our support as a result of our indemnification agreements or may result in restrictions in the operations of our or our managers’ or sub-managers’ business.

Events that adversely affect the ability of seniors and their families to afford resident fees at our seniors housing facilities could cause our occupancy rates, revenues and results of operations to decline.

Costs to seniors associated with independent, assisted living and memory care services are generally not reimbursable under government reimbursement programs such as Medicare and Medicaid. Only seniors with sufficient income or assets or other resources will be able to afford to pay the monthly resident fees, and a weak economy, depressed housing market or changes in demographics could adversely affect their continued ability to do so. If our managers or sub-managers are unable to retain and attract seniors with sufficient income, assets or other resources required to pay the fees associated with independent and assisted living services, our occupancy rates and revenues could decline, which could, in turn, materially adversely affect our business, results of operations and financial condition.

Our ability to lease certain of our seniors housing facilities to our TRS lessee will be limited by the ability of those seniors housing facilities to qualify as “qualified healthcare properties.”

We lease certain of our seniors housing facilities to our TRS lessee, which contracts with managers to manage the healthcare operations at those facilities. Our ability to use this TRS lessee structure may be limited by the ability of those seniors housing facilities to qualify as “qualified healthcare properties” and the ability of the managers who our TRS lessee engages to manage the “qualified healthcare properties” to qualify as “eligible independent contractors.”

A “qualified healthcare property” includes any real property and any personal property that is, or is necessary or incidental to the use of, a hospital, nursing facility, assisted living facility, congregate care facility, qualified continuing care facility or other licensed facility which extends medical or nursing or ancillary services to patients and which is operated by a provider of such services which is eligible for participation in the Medicare program with respect to such facilities. Some of our properties may not be treated as “qualified healthcare properties.” To the extent a property does not constitute a “qualified healthcare property,” we will be unable to use the TRS lessee structure with respect to that property.

If our TRS lessee failed to qualify as a TRS or the facility managers engaged by our TRS lessee do not qualify as “eligible independent contractors,” we could fail to qualify as a REIT and could be subject to higher taxes.

Rent paid by a lessee that is a “related party tenant” of ours will not be qualifying income for purposes of the two gross income tests applicable to REITs. We lease certain of our seniors housing facilities that qualify as “qualified healthcare properties” to our TRS lessee. So long as our TRS lessee qualifies as a TRS, it will not be treated as a “related party tenant” with respect to our “qualified healthcare properties” that are managed by an independent facility manager that qualifies as an “eligible independent contractor.” We expect that our TRS lessee will qualify to be treated as a TRS for U.S. federal income tax purposes, but there can be no assurance that the IRS will not challenge the status of our TRS lessee for U.S. federal income tax purposes or that a court would not sustain such a challenge. If the IRS were successful in disqualifying our TRS lessee from treatment as a TRS, we could fail to meet the asset tests applicable to REITs and we could fail to satisfy the gross income tests. If we failed to meet either the asset or gross income tests, we could lose our REIT qualification for U.S. federal income tax purposes unless we qualified for application of statutory savings provisions.

Additionally, if the managers engaged by our TRS lessee do not qualify as “eligible independent contractors,” we could fail to qualify as a REIT. Each of the managers that enter into a management contract with our TRS lessee must qualify as an “eligible independent contractor” under the REIT rules in order for the rent paid to us by our TRS lessee to be qualifying income for purposes of the REIT gross income tests. Among other requirements, in order to qualify as an eligible independent contractor, a manager must not own, directly or indirectly, more than 35% of our outstanding stock and no person or group of persons can own more than 35% of our

-52-

Table of Contents

outstanding stock and the ownership interests of the manager, taking into account certain ownership attribution rules. The ownership attribution rules that apply for purposes of these 35% thresholds are complex. Although we intend to monitor ownership of our stock by our managers and their owners, there can be no assurance that these ownership levels will not be exceeded.

In addition, in order to qualify as an “eligible independent contractor,” among other requirements, a manager (or a related person) must be actively engaged in the trade or business of operating “qualified healthcare properties” for persons who are not related to us or our TRS lessee. Consequently, if a manager (or a related person) with respect to a “qualified healthcare property” of ours does not operate sufficient “qualified healthcare properties” for third parties, the manager will not qualify as an “eligible independent contractor.”

The ability of our TRSs to manage certain of our independent living facilities will be dependent on such facilities not constituting “qualified healthcare properties.”

We engage TRSs to manage certain of our independent living facilities. Our ability to utilize TRSs in such a role depends on those independent living facilities not constituting “qualified healthcare properties” within the meaning of the U.S. federal income tax rules applicable to REITs. While we believe that such independent living facilities are not “qualified healthcare properties,” if the IRS challenged such belief and a court sustained such a challenge, our income from the properties could fail to qualify as rents from real property for purposes of the REIT gross income tests, and as a result we could fail to qualify as a REIT.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Securities

On May 29, 2026 and June 2, 2026, the Company completed closings of its previously announced private placement pursuant to which it issued and sold an aggregate of 1,000,000 shares of its 6.00% Series C Convertible Preferred Stock, par value $0.001 per share, at a purchase price of $100.00 per share for aggregate gross proceeds of $100.0 million, to Maewyn XRN LP, Petrus Special Opportunities Fund, L.P., certain entities advised by Canyon Capital Advisors LLC and certain entities advised by Diameter Capital Partners LP (the “Purchasers”), pursuant to that certain Investment Agreement, dated as of May 6, 2026, by and among the Company and the Purchasers.

The offer and sale of the shares of Series C Convertible Preferred Stock were not registered under the Securities Act of 1933, as amended (the “Securities Act”), and were made in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. The Company relied on these exemptions from registration based in part on the nature of the transaction and the representations made by the Purchasers in the Investment Agreement.

Upon completion of the private placement, the Company received net proceeds of approximately $96.8 million, after deducting a commitment fee of $3.0 million and reimbursable expenses of approximately $0.2 million. The Company contributed the proceeds received from the sale of the Series C Convertible Preferred Stock to the Operating Partnership in exchange for the issuance of 1,000,000 Series C Convertible Preferred Units. The Company used the net proceeds from the private placement, together with cash on hand and borrowings under its Credit Facility, to fund the acquisitions of the Landing and the Riviera.

Holders of the Series C Convertible Preferred Stock have the option to convert their shares into shares of the Company’s common stock at any time at the then-effective conversion rate (the “Conversion Rate”). The initial Conversion Rate of the Series C Convertible Preferred Stock is 2.32558 shares of common stock, based on an implied conversion price of $43.00 per share of common stock. Beginning on June 2, 2029, the Company has the option to convert the Series C Convertible Preferred Stock to common stock if the volume-weighted average price of its common stock exceeds 120.0% of the conversion price for 45 consecutive trading days.

Issuer Purchases of Equity Securities

None.

Item 3. Defaults Upon Senior Securities

None.

-53-

Table of Contents

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

-54-

Table of Contents

Item 6. Exhibits

(a)Exhibits

Exhibit No.

  ​ ​ ​

Description

3.1

Articles of Restatement of Chiron Real Estate Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q as filed with the SEC on August 8, 2018).

3.2

Articles of Amendment of Chiron Real Estate Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed with the SEC on September 19, 2025).

3.3

Articles Supplementary for Chiron Real Estate Inc. 8.00% Series B Cumulative Redeemable Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed with the SEC on November 18, 2025).

3.4

Articles of Amendment of Chiron Real Estate Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed with the SEC on February 25, 2026).

3.5

Articles Supplementary, classifying and designating 3,000,000 additional shares of Series B Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed with the SEC on March 13, 2026).

3.6

Articles Supplementary for Chiron Real Estate Inc. 6.00% Series C Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed with the SEC on June 2, 2026).

3.7

Fifth Amended and Restated Bylaws of Chiron Real Estate Inc., effective as of February 23, 2026 (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K as filed with the SEC on February 25, 2026).

4.1

Specimen of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-11/A as filed with the SEC on June 15, 2016).

4.2

Specimen of 7.50% Series A Cumulative Redeemable Preferred Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed with the SEC on September 14, 2017).

4.3

Specimen of 8.00% Series B Cumulative Redeemable Preferred Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed with the SEC on November 18, 2025).

10.1

Seventh Amendment to Agreement of Limited Partnership of Chiron Real Estate LP, dated as of May 28, 2026 (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the SEC on June 2, 2026).

10.2*

Asset Purchase Agreement, by and between XRN Alexandria I LLC and Silverstone Alexandria II Owner, LLC, dated as of May 1, 2026.

10.3*

First Amendment to Asset Purchase Agreement, by and between XRN Alexandria I LLC and Silverstone Alexandria II Owner, LLC, dated as of May 29, 2026.

10.4*

Purchase and Sale Agreement, by and among XRN Alexandria II LLC, Silverstone Alexandria, LP and Silverstone Alexandria Owner, LLC, dated as of May 1, 2026.

10.5*

PSA Side Letter Agreement, by and between SSL Investment Partners, L.P., and XRN Alexandria II LLC, dated as of May 1, 2026.

-55-

Table of Contents

10.6*

First Amendment to Purchase and Sale Agreement, by and among XRN Alexandria I LLC, Silverstone Alexandria, LP and Silverstone Alexandria Owner, LLC, dated as of May 29, 2026.

10.7*

Asset Purchase Agreement, by and among XRN Bethesda, LLC and Silverstone Bethesda Owner, LLC, dated as of May 6, 2026.

10.8*

First Amendment to Asset Purchase Agreement, by and between XRN Bethesda, LLC and Silverstone Bethesda Owner, LLC, dated as of June 22, 2026.

10.9

Investment Agreement, dated as of May 6, 2026, by and among Chiron Real Estate Inc. and Maewyn XRN LP (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the SEC on May 8, 2026).

10.10

Investor Rights Agreement, dated as of May 6, 2026, by and among Chiron Real Estate Inc. and Maewyn XRN LP (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the SEC on May 8, 2026).

10.11

Amendment No. 1 to the Investor Rights Agreement, dated as of May 28, 2026, by and among Chiron Real Estate Inc. and Maewyn XRN LP (incorporated herein by reference to Exhibit 4.12 to the Company’s Registration Statement on Form S-3 (File No. 333-296829) as filed with the SEC on June 16, 2026).

10.12

Chiron Real Estate Inc. 2016 Equity Incentive Plan (as amended through May 20, 2026) (incorporated herein by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-8 (File No. 333-297159) as filed with the SEC on June 30, 2026).

10.13

Agreement of Purchase and Sale, dated as of June 26, 2026, by and among certain subsidiaries of Chiron Real Estate Inc., as sellers, the buyers party thereto, and Chiron Real Estate LP, solely for the limited purposes set forth therein (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the SEC on July 2, 2026).

31.1*

Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of Principal Executive Officer and Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS *

Inline XBRL Instance Document

101.SCH *

Inline XBRL Taxonomy Schema

101.CAL *

Inline XBRL Taxonomy Calculation Linkbase

101.DEF *

Inline XBRL Taxonomy Definition Linkbase

101.LAB *

Inline XBRL Taxonomy Label Linkbase

101.PRE *

Inline XBRL Taxonomy Presentation Linkbase

104

Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)

*

Filed herewith.

**

Furnished herewith. Such certification shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

-56-

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Chiron Real Estate Inc.

Date: August 10, 2026

By:

/s/ Mark O. Decker, Jr.

Mark O. Decker, Jr.

Chief Executive Officer (Principal Executive Officer)

Date: August 10, 2026

By:

/s/ Robert J. Kiernan

Robert J. Kiernan

Chief Financial Officer (Principal Financial and Accounting Officer)

-57-